Gary Herbert Lyman
Adjunct Professor in the Department of Medicine
Dr. Gary Lyman is Professor of Medicine in the Division of Medical Oncology, Department of Internal Medicine at Duke University School of Medicine and the Duke Cancer Institute. He serves as Director of the Comparative Effectiveness and Outcomes Research Program in Oncology. Dr Lyman is also Senior Fellow in the Duke Center for Clinical Health Policy Research. He is a nationally and internationally recognized authority on comparative effectiveness and health services and outcomes research. Lyman research is funded by the National Cancer Institute, the National Heart Lung and Blood Institute, the American Society of Clinical Oncology along with industry grants related to supportive cancer care. Dr Lyman has published some 400 research articles in in the professional medical literature. Direct funding from all sources supports an annual Comparative Effectiveness and Outcomes Research budget of over $5 million.
Dr Lyman’s research interests include:
Personalized Medicine and Cancer Supportive Care: In addition to the conduct of randomized controlled trials of new cancer diagnostic, prognostic, treatment and supportive care approaches, Dr Lyman’s research interests include the personalized management of early-stage breast cancer and supportive care of patients receiving cancer chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Based on clinical trial results, Dr Lyman is actively involved in the development and validation of clinical risk models for patient selection and targeted intervention and preventive strategies. Dr Lyman is co-PI on an NCI on comparative effectiveness of cancer pharmacogenomics grant to discover and validate new genomic tools for guiding more personalized cancer treatments and on an NHLBI trial of thromboprophylaxis in high risk ambulatory patients receiving cancer chemotherapy.
Evidence synthesis, clinical practice guidelines and health policy: Dr Lyman conducts systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. Dr Lyman chairs several guidelines for the American Society of Clinical Oncology including those on antiemetics, venous thromboembolism, sentinel node biopsy in patients with breast cancer and cutaneous melanoma and on weight based dosing of chemotherapy. Dr Lyman also conducts analyses of large population studies of clinical outcomes associated with of current cancer patient management in a real world setting with a particular focus on cancer management in the elderly patient with cancer. Dr Lyman leads several decision simulation studies for improved clinical decision making and cost-effectiveness analysis of new and novel therapies based on results of clinical trials, systematic reviews and population studies. He serves as an advisor on new oncologic agents to the US FDA. Dr Lyman also serves as Editor-in-Chief of Cancer Investigation and on the editorial boards of several prestigious research journals.
Dr Lyman’s research interests include:
Personalized Medicine and Cancer Supportive Care: In addition to the conduct of randomized controlled trials of new cancer diagnostic, prognostic, treatment and supportive care approaches, Dr Lyman’s research interests include the personalized management of early-stage breast cancer and supportive care of patients receiving cancer chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Based on clinical trial results, Dr Lyman is actively involved in the development and validation of clinical risk models for patient selection and targeted intervention and preventive strategies. Dr Lyman is co-PI on an NCI on comparative effectiveness of cancer pharmacogenomics grant to discover and validate new genomic tools for guiding more personalized cancer treatments and on an NHLBI trial of thromboprophylaxis in high risk ambulatory patients receiving cancer chemotherapy.
Evidence synthesis, clinical practice guidelines and health policy: Dr Lyman conducts systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. Dr Lyman chairs several guidelines for the American Society of Clinical Oncology including those on antiemetics, venous thromboembolism, sentinel node biopsy in patients with breast cancer and cutaneous melanoma and on weight based dosing of chemotherapy. Dr Lyman also conducts analyses of large population studies of clinical outcomes associated with of current cancer patient management in a real world setting with a particular focus on cancer management in the elderly patient with cancer. Dr Lyman leads several decision simulation studies for improved clinical decision making and cost-effectiveness analysis of new and novel therapies based on results of clinical trials, systematic reviews and population studies. He serves as an advisor on new oncologic agents to the US FDA. Dr Lyman also serves as Editor-in-Chief of Cancer Investigation and on the editorial boards of several prestigious research journals.
Current Appointments & Affiliations
- Adjunct Professor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2014
Contact Information
- 2424 Erwin Road, Suite 205, Durham, NC 27705
- Duke Box 2736, 2424 Erwin Road, Durham, NC 27705
-
gary.lyman@duke.edu
(919) 681-1736
- Background
-
Education, Training, & Certifications
- Research Fellow, Medicine, Dana-Farber Cancer Institute 1981 - 1982
- Medical Oncology Clinical Fellowship, Medicine, Roswell Park Cancer Institute 1974 - 1976
- Intern and Junior Assistant Resident, Medicine, University of North Carolina - Chapel Hill 1972 - 1974
- M.D., State University of New York - Buffalo 1972
-
Previous Appointments & Affiliations
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2007 - 2014
- Professor of Medicine, Medicine, Medical Oncology, Medicine 2008 - 2013
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2008
- Recognition
-
In the News
-
SEP 19, 2013 The Atlanta Journal-Constitution
-
- Research
-
Selected Grants
- Programs in Clinical Effectiveness of Cancer Pharmacogenomics awarded by National Institutes of Health 2009 - 2012
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Lyman, G. H., M. Reiner, P. K. Morrow, and J. Crawford. “The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.” Ann Oncol 26, no. 7 (July 2015): 1452–58. https://doi.org/10.1093/annonc/mdv174.Full Text Link to Item
-
Lyman, Gary H., Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.” J Clin Oncol 33, no. 6 (February 20, 2015): 654–56. https://doi.org/10.1200/JCO.2014.59.7351.Full Text Link to Item
-
Dinan, Michaela A., Bradford R. Hirsch, and Gary H. Lyman. “Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.” J Natl Compr Canc Netw 13, no. 1 (January 2015): e1–7. https://doi.org/10.6004/jnccn.2015.0014.Full Text Link to Item
-
Culakova, Eva, Marek S. Poniewierski, Debra A. Wolff, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.” Springerplus 4 (2015): 396. https://doi.org/10.1186/s40064-015-1165-6.Full Text Link to Item
-
Fust, Kelly, Xiaoyan Li, Michael Maschio, Richard Barron, Milton C. Weinstein, Anju Parthan, Marjan Walli-Attaei, David B. Chandler, and Gary H. Lyman. “Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.” Gynecol Oncol 133, no. 3 (June 2014): 446–53. https://doi.org/10.1016/j.ygyno.2014.03.014.Full Text Link to Item
-
Weycker, Derek, Richard Barron, Alex Kartashov, Jason Legg, and Gary H. Lyman. “Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.” J Oncol Pharm Pract 20, no. 3 (June 2014): 190–98. https://doi.org/10.1177/1078155213492450.Full Text Link to Item
-
Hoang, J. K., K. R. Choudhury, J. D. Eastwood, R. M. Esclamado, G. H. Lyman, T. M. Shattuck, and X. V. Nguyen. “An exponential growth in incidence of thyroid cancer: trends and impact of CT imaging.” Ajnr Am J Neuroradiol 35, no. 4 (April 2014): 778–83. https://doi.org/10.3174/ajnr.A3743.Full Text Link to Item
-
Brücher, B. L. D. M., G. Lyman, R. V. Hillegersberg, R. E. Pollock, F. Lordick, H. K. Yang, T. Ushijima, et al. “Imagine a world without cancer.” Bmc Cancer 14, no. 1 (2014). https://doi.org/10.1186/1471-2407-14-186.Full Text
-
Buchholz, T. A., M. R. Somerfield, J. J. Griggs, S. El-Eid, M. E. H. Hammond, G. H. Lyman, G. Mason, and L. A. Newman. “Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 14 (2014): 1502–6. https://doi.org/10.1200/JCO.2014.55.1572.Full Text
-
Hill, Gregory, Richard Barron, Kelly Fust, Michelle E. Skornicki, Douglas C. A. Taylor, Milton C. Weinstein, and Gary H. Lyman. “Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.” J Med Econ 17, no. 1 (January 2014): 32–42. https://doi.org/10.3111/13696998.2013.844160.Full Text Link to Item
-
Kuderer, N. M., and G. H. Lyman. “Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.” Thrombosis Research 133, no. SUPPL. 2 (2014): S122–27. https://doi.org/10.1016/S0049-3848(14)50021-7.Full Text
-
Lyman, G. H. “Impact of venous thromboembolism on survival in patients with advanced cancer: An unmet clinical need.” Internal and Emergency Medicine 9, no. 5 (2014): 497–99. https://doi.org/10.1007/s11739-014-1087-2.Full Text
-
Lyman, G. H., E. Abella, and R. Pettengell. “Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.” Critical Reviews in Oncology/Hematology 90, no. 3 (2014): 190–99. https://doi.org/10.1016/j.critrevonc.2013.12.006.Full Text
-
Lyman, G. H., S. Temin, S. B. Edge, L. A. Newman, R. R. Turner, D. L. Weaver, A. B. B. 3rd, et al. “Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 13 (2014): 1365–83. https://doi.org/10.1200/JCO.2013.54.1177.Full Text
-
Weycker, D., X. Li, J. Edelsberg, R. Barron, A. Kartashov, H. Xu, and G. H. Lyman. “Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.” Supportive Care in Cancer, 2014. https://doi.org/10.1007/s00520-014-2362-5.Full Text
-
Wong, F. L., S. Bhatia, W. Landier, L. Francisco, W. Leisenring, M. M. Hudson, G. T. Armstrong, et al. “Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.” Annals of Internal Medicine 160, no. 10 (2014): 672–83. https://doi.org/10.7326/M13-2498.Full Text
-
Lyman, Gary H., Alok A. Khorana, Nicole Kuderer, Ann Alexis Prestrud, and Anna Falanga. “Reply to T.H. Oo.” J Clin Oncol 31, no. 34 (December 1, 2013): 4381–82. https://doi.org/10.1200/JCO.2013.52.6244.Full Text Link to Item
-
Schnipper, Lowell E., Gary H. Lyman, Douglas W. Blayney, J Russell Hoverman, Derek Raghavan, Dana S. Wollins, and Richard L. Schilsky. “American Society of Clinical Oncology 2013 top five list in oncology.” J Clin Oncol 31, no. 34 (December 1, 2013): 4362–70. https://doi.org/10.1200/JCO.2013.53.3943.Full Text Link to Item
-
Lyman, Gary H., and Alex Sparreboom. “Appropriate chemotherapy dosing in obese patients with cancer.” Nat Rev Clin Oncol 10, no. 11 (November 2013): 664. https://doi.org/10.1038/nrclinonc.2013.108-c2.Full Text Link to Item
-
Lyman, Gary H. “Counting the costs of cancer care.” Lancet Oncol 14, no. 12 (November 2013): 1142–43. https://doi.org/10.1016/S1470-2045(13)70480-7.Full Text Link to Item
-
Peppercorn, Jeffrey, Erika Hamilton, Paul Kelly Marcom, Laura Beskow, and Gary H. Lyman. “Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.” Cancer 119, no. 20 (October 15, 2013): 3703–9. https://doi.org/10.1002/cncr.28263.Full Text Link to Item
-
Hirsch, Bradford R., and Gary H. Lyman. “Will biosimilars gain momentum?” J Natl Compr Canc Netw 11, no. 10 (October 1, 2013): 1291–97. https://doi.org/10.6004/jnccn.2013.0149.Full Text Link to Item
-
Shayne, Michelle, Eva Culakova, Marek S. Poniewierski, David C. Dale, Jeffrey Crawford, Adane F. Wogu, and Gary H. Lyman. “Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.” J Geriatr Oncol 4, no. 4 (October 2013): 310–18. https://doi.org/10.1016/j.jgo.2013.05.005.Full Text Link to Item
-
Crawford, Jeffrey, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, et al. “Myeloid growth factors.” J Natl Compr Canc Netw 11, no. 10 (October 1, 2013): 1266–90. https://doi.org/10.6004/jnccn.2013.0148.Full Text Link to Item
-
Lyman, G. H., D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff, N. M. Kuderer, M. Huang, and J. Crawford. “The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.” Ann Oncol 24, no. 10 (October 2013): 2475–84. https://doi.org/10.1093/annonc/mdt226.Full Text Link to Item
-
Walenga, Jeanine M., and Gary H. Lyman. “Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.” Crit Rev Oncol Hematol 88, no. 1 (October 2013): 1–18. https://doi.org/10.1016/j.critrevonc.2013.06.007.Full Text Link to Item
-
Nguyen, X. V., K Roy Choudhury, J. D. Eastwood, G. H. Lyman, R. M. Esclamado, J. D. Werner, and J. K. Hoang. “Incidental thyroid nodules on CT: evaluation of 2 risk-categorization methods for work-up of nodules.” Ajnr Am J Neuroradiol 34, no. 9 (September 2013): 1812–17. https://doi.org/10.3174/ajnr.A3487.Full Text Link to Item
-
Lyman, Gary H., and Alex Sparreboom. “Chemotherapy dosing in overweight and obese patients with cancer.” Nat Rev Clin Oncol 10, no. 8 (August 2013): 451–59. https://doi.org/10.1038/nrclinonc.2013.108.Full Text Link to Item
-
Simonds, Naoko I., Muin J. Khoury, Sheri D. Schully, Katrina Armstrong, Wendy F. Cohn, David A. Fenstermacher, Geoffrey S. Ginsburg, et al. “Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.” J Natl Cancer Inst 105, no. 13 (July 3, 2013): 929–36. https://doi.org/10.1093/jnci/djt108.Full Text Link to Item
-
Lyman, Gary H., Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, Jeffrey M. Clarke, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.” J Clin Oncol 31, no. 17 (June 10, 2013): 2189–2204. https://doi.org/10.1200/JCO.2013.49.1118.Full Text Link to Item
-
Lyman, Gary H. “Comparative effectiveness research in oncology.” Oncologist 18, no. 6 (June 2013): 752–59. https://doi.org/10.1634/theoncologist.2012-0445.Full Text Link to Item
-
Lyman, Gary H., David C. Dale, Dianne Tomita, Sadie Whittaker, and Jeffrey Crawford. “A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.” Breast Cancer Res Treat 139, no. 3 (June 2013): 863–72. https://doi.org/10.1007/s10549-013-2582-2.Full Text Link to Item
-
Zhang, Tian, Andrew Schneider, Erika P. Hamilton, Krish Patel, Arif H. Kamal, Gary H. Lyman, and Jeffrey M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” Breast Cancer Res Treat 139, no. 3 (June 2013): 845–50. https://doi.org/10.1007/s10549-013-2590-2.Full Text Link to Item
-
Hanna, Rabbie K., Marek S. Poniewierski, Robin A. Laskey, Micael A. Lopez, Aaron Shafer, Linda Van Le, Jeffrey Crawford, et al. “Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.” Gynecol Oncol 129, no. 1 (April 2013): 74–80. https://doi.org/10.1016/j.ygyno.2012.12.017.Full Text Link to Item
-
Lyman, Gary H., Jay Baker, Joseph Geradts, Janet Horton, Gretchen Kimmick, Jeffrey Peppercorn, Scott Pruitt, Randall P. Scheri, and E Shelley Hwang. “Multidisciplinary care of patients with early-stage breast cancer.” Surg Oncol Clin N Am 22, no. 2 (April 2013): 299–317. https://doi.org/10.1016/j.soc.2012.12.005.Full Text Link to Item
-
Hirsch, B. R., S. D. Reed, and G. H. Lyman. “Update on the role of epothilones in metastatic breast cancer.” Current Breast Cancer Reports 5, no. 1 (March 1, 2013): 51–56. https://doi.org/10.1007/s12609-012-0095-3.Full Text
-
Reed, Shelby D., Michaela A. Dinan, Kevin A. Schulman, and Gary H. Lyman. “Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.” Genet Med 15, no. 3 (March 2013): 203–11. https://doi.org/10.1038/gim.2012.119.Full Text Link to Item
-
Rajan, Suja S., William R. Carpenter, Sally C. Stearns, and Gary H. Lyman. “Short-term costs associated with primary prophylactic G-CSF use during chemotherapy.” Am J Manag Care 19, no. 2 (February 2013): 150–59.Link to Item
-
Lyman, G. H. “Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. (Cancer Investigation (2013) 31:1 (24-8) DOI: 10.3109/07357907.2012.716468).” Cancer Investigation 31, no. 10 (2013): 661-. https://doi.org/10.3109/07357907.2013.854525.Full Text
-
Lyman, G. H., and A. Treadway. “Statement of retraction: Hongying Lv, Qicai Li, Wengsheng Qiu, Jinyu Xiang, Hongjun Wei, Hua Liang, Aihua Sui and Jun Liang "Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer".” Cancer Investigation 31, no. 10 (2013): 661-.
-
Lyman, Gary H., Alok A. Khorana, and Anna Falanga. “Thrombosis and cancer: emerging data for the practicing oncologist.” Am Soc Clin Oncol Educ Book, 2013. https://doi.org/10.14694/EdBook_AM.2013.33.e337.Full Text Link to Item
-
Lyman, Gary H., Laurent Eckert, Yanxin Wang, Hongwei Wang, and Alexander Cohen. “Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis.” Oncologist 18, no. 12 (2013): 1321–29. https://doi.org/10.1634/theoncologist.2013-0226.Full Text Link to Item
-
Reed, Shelby D., and Gary H. Lyman. “Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.” Cancer 118, no. 24 (December 15, 2012): 6298–99. https://doi.org/10.1002/cncr.27665.Full Text Link to Item
-
Carrier, M., A. A. Khorana, J. I. Zwicker, G. H. Lyman, G. Le Gal, A. Y. Y. Lee, and A. Y. Y. subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. “Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis.” J Thromb Haemost 10, no. 12 (December 2012): 2599–2601. https://doi.org/10.1111/jth.12028.Full Text Link to Item
-
Hornberger, John, Gary H. Lyman, Rebecca Chien, and Neal J. Meropol. “A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.” Value Health 15, no. 8 (December 2012): 1014–21. https://doi.org/10.1016/j.jval.2012.07.012.Full Text Link to Item
-
Lyman, Gary H., and Mark Levine. “Epilogue: the peril and the promise of comparative effectiveness research in oncology.” J Clin Oncol 30, no. 34 (December 1, 2012): 4282. https://doi.org/10.1200/JCO.2012.45.9800.Full Text Link to Item
-
Lyman, Gary H., and Mark Levine. “Comparative effectiveness research in oncology: an overview.” J Clin Oncol 30, no. 34 (December 1, 2012): 4181–84. https://doi.org/10.1200/JCO.2012.45.9792.Full Text Link to Item
-
Lyman, G. H., and J. J. Griggs. “Reply to P.K.L. Chin et al, P. Chambers et al, and J.H. Beumer et al.” Journal of Clinical Oncology 30, no. 31 (November 1, 2012): 3898–99. https://doi.org/10.1200/JCO.2012.44.8654.Full Text
-
Hirsch, B. R., and G. H. Lyman. “Economics of the recombinant human granulocyte colony-stimulating factors.” Milestones in Drug Therapy 43 (October 8, 2012): 409–20. https://doi.org/10.1007/978-3-0348-0218-5_22.Full Text
-
Lyman, Gary H., Harold J. Burstein, Aman U. Buzdar, Ralph D’Agostino, and Paul A. Ellis. “Making genuine progress against metastatic breast cancer.” J Clin Oncol 30, no. 28 (October 1, 2012): 3448–51. https://doi.org/10.1200/JCO.2012.43.6931.Full Text Link to Item
-
Wong, Sandra L., Charles M. Balch, Patricia Hurley, Sanjiv S. Agarwala, Timothy J. Akhurst, Alistair Cochran, Janice N. Cormier, et al. “Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.” Ann Surg Oncol 19, no. 11 (October 2012): 3313–24. https://doi.org/10.1245/s10434-012-2475-3.Full Text Link to Item
-
Loblaw, D Andrew, Ann Alexis Prestrud, Mark R. Somerfield, Thomas K. Oliver, Melissa C. Brouwers, Robert K. Nam, Gary H. Lyman, Ethan Basch, and Ethan Americal Society of Clinical Oncology Clinical Practice Guidelines. “American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology.” J Clin Oncol 30, no. 25 (September 1, 2012): 3136–40. https://doi.org/10.1200/JCO.2012.42.0489.Full Text Link to Item
-
Michels, Shannon L., Rich L. Barron, Matthew W. Reynolds, Karen Smoyer Tomic, Jingbo Yu, and Gary H. Lyman. “Costs associated with febrile neutropenia in the US.” Pharmacoeconomics 30, no. 9 (September 1, 2012): 809–23. https://doi.org/10.2165/11592980-000000000-00000.Full Text Link to Item
-
Wong, Sandra L., Charles M. Balch, Patricia Hurley, Sanjiv S. Agarwala, Timothy J. Akhurst, Alistair Cochran, Janice N. Cormier, et al. “Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.” J Clin Oncol 30, no. 23 (August 10, 2012): 2912–18. https://doi.org/10.1200/JCO.2011.40.3519.Full Text Link to Item
-
Goddard, Katrina A. B., William A. Knaus, Evelyn Whitlock, Gary H. Lyman, Heather Spencer Feigelson, Sheri D. Schully, Scott Ramsey, et al. “Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.” Genet Med 14, no. 7 (July 2012): 633–42. https://doi.org/10.1038/gim.2012.16.Full Text Link to Item
-
Griggs, J. J., P. B. Mangu, S. Temin, and G. H. Lyman. “Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice guideline.” Journal of Oncology Practice 8, no. 4 (July 1, 2012). https://doi.org/10.1200/JOP.2012.000623.Full Text
-
Khorana, Alok A., Alex C. Spyropoulos, Jeffrey Zwicker, Gary H. Lyman, and Charles W. Francis. “Preventing VTE in Outpatients With Cancer.” Chest 142, no. 1 (July 2012): 265–66. https://doi.org/10.1378/chest.12-0423.Full Text Link to Item
-
Lyman, Gary H. “Weight-based chemotherapy dosing in obese patients with cancer: back to the future.” J Oncol Pract 8, no. 4 (July 2012): e62–64. https://doi.org/10.1200/JOP.2012.000606.Full Text Link to Item
-
Wong, S. L., P. Hurley, and G. H. Lyman. “Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice guideline.” Journal of Oncology Practice 8, no. 4 (July 1, 2012). https://doi.org/10.1200/JOP.2012.000676.Full Text
-
Extermann, Martine, Ivette Boler, Richard R. Reich, Gary H. Lyman, Richard H. Brown, Joseph DeFelice, Richard M. Levine, et al. “Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.” Cancer 118, no. 13 (July 1, 2012): 3377–86. https://doi.org/10.1002/cncr.26646.Full Text Link to Item
-
Hirsch, Bradford R., and Gary H. Lyman. “Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.” Pharmacoeconomics 30, no. 6 (June 1, 2012): 497–511. https://doi.org/10.2165/11590130-000000000-00000.Full Text Link to Item
-
Laskey, Robin A., Marek S. Poniewierski, Micael A. Lopez, Rabbie K. Hanna, Angeles Alvarez Secord, Paola A. Gehrig, Gary H. Lyman, and Laura J. Havrilesky. “Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.” Gynecol Oncol 125, no. 3 (June 2012): 625–30. https://doi.org/10.1016/j.ygyno.2012.03.015.Full Text Link to Item
-
Griggs, Jennifer J., Pamela B. Mangu, Holly Anderson, Edward P. Balaban, James J. Dignam, William M. Hryniuk, Vicki A. Morrison, et al. “Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.” J Clin Oncol 30, no. 13 (May 1, 2012): 1553–61. https://doi.org/10.1200/JCO.2011.39.9436.Full Text Link to Item
-
Weycker, Derek, Rich Barron, John Edelsberg, Alex Kartashov, and Gary H. Lyman. “Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.” Breast Cancer Res Treat 133, no. 1 (May 2012): 301–10. https://doi.org/10.1007/s10549-011-1949-5.Full Text Link to Item
-
Lyman, Gary H., Richard L. Barron, Jaime L. Natoli, and Ross M. Miller. “Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.” Crit Rev Oncol Hematol 81, no. 3 (March 2012): 296–308. https://doi.org/10.1016/j.critrevonc.2011.04.010.Full Text Link to Item
-
Hurwitz, Herbert I., and Gary H. Lyman. “Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?” J Clin Oncol 30, no. 6 (February 20, 2012): 580–81. https://doi.org/10.1200/JCO.2011.40.7031.Full Text Link to Item
-
Acharya, Chaitanya R., David S. Hsu, Carey K. Anders, Ariel Anguiano, Kelly H. Salter, Kelli S. Walters, Richard C. Redman, et al. “Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.” Jama 307, no. 5 (February 1, 2012): 453. https://doi.org/10.1001/jama.2012.2.Full Text Link to Item
-
Griffiths, Robert I., Richard L. Barron, Michelle L. Gleeson, Mark D. Danese, Anthony O’Hagan, Victoria M. Chia, Jason C. Legg, and Gary H. Lyman. “Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.” Pharmacoeconomics 30, no. 2 (February 1, 2012): 103–18. https://doi.org/10.2165/11589440-000000000-00000.Full Text Link to Item
-
Lyman, Gary H. “The incidence of venous thromboembolism in cancer patients: a real-world analysis.” Clin Adv Hematol Oncol 10, no. 1 (January 2012): 40–42.Link to Item
-
Weycker, Derek, John Edelsberg, Alex Kartashov, Rich Barron, and Gary Lyman. “Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.” Chemotherapy 58, no. 1 (2012): 8–18. https://doi.org/10.1159/000335604.Full Text Link to Item
-
Lyman, G. H., S. L. Michels, and R. Barron. “Reply to risk of mortality in patients with cancer who experience febrile neutropenia.” Cancer 117, no. 22 (November 15, 2011): 5246. https://doi.org/10.1002/cncr.26141.Full Text
-
Basch, Ethan, Ann Alexis Prestrud, Paul J. Hesketh, Mark G. Kris, Petra C. Feyer, Mark R. Somerfield, Maurice Chesney, et al. “Antiemetics: American Society of Clinical Oncology clinical practice guideline update.” J Clin Oncol 29, no. 31 (November 1, 2011): 4189–98. https://doi.org/10.1200/JCO.2010.34.4614.Full Text Link to Item
-
Basch, Ethan, Mark R. Somerfield, Ann Partridge, Lowell Schnipper, and Gary H. Lyman. “Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?” J Oncol Pract 7, no. 6 (November 2011): 398–401. https://doi.org/10.1200/JOP.2011.000414.Full Text Link to Item
-
Basch, Ethan, Paul J. Hesketh, Mark G. Kris, Ann Alexis Prestrud, Sarah Temin, and Gary H. Lyman. “Antiemetics: american society of clinical oncology clinical practice guideline update.” J Oncol Pract 7, no. 6 (November 2011): 395–98. https://doi.org/10.1200/JOP.2011.000397.Full Text Link to Item
-
Rajan, Suja S., Sally C. Stearns, Gary H. Lyman, and William R. Carpenter. “Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients.” Breast Cancer Res Treat 130, no. 1 (November 2011): 255–66. https://doi.org/10.1007/s10549-011-1553-8.Full Text Link to Item
-
Zeliadt, Steven B., Nishant K. Sekaran, Elaine Y. Hu, Christopher C. Slatore, David H. Au, Leah Backhus, Daniel Y. Wu, Jeffrey Crawford, Gary H. Lyman, and David C. Dale. “Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest.” J Thorac Oncol 6, no. 10 (October 2011): 1726–32. https://doi.org/10.1097/JTO.0b013e31822ada77.Full Text Link to Item
-
Lyman, G. H., H. I. Hurwitz, F. Sirzén, and U. P. Rohr. “Reply to S. Hapani et al.” Journal of Clinical Oncology 29, no. 25 (September 1, 2011): 3490–91. https://doi.org/10.1200/JCO.2011.36.5692.Full Text
-
Zelenetz, Andrew D., Islah Ahmed, Edward Louis Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, et al. “NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.” J Natl Compr Canc Netw 9 Suppl 4 (September 2011): S1-22. https://doi.org/10.6004/jnccn.2011.0136.Full Text Link to Item
-
Rosa, Nicole de, Gary H. Lyman, Damian Silbermins, Matias E. Valsecchi, Scott K. Pruitt, Douglas M. Tyler, and Walter T. Lee. “Sentinel node biopsy for head and neck melanoma: a systematic review.” Otolaryngol Head Neck Surg 145, no. 3 (September 2011): 375–82. https://doi.org/10.1177/0194599811408554.Full Text Link to Item
-
Crawford, Jeffrey, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, et al. “Myeloid growth factors.” J Natl Compr Canc Netw 9, no. 8 (August 1, 2011): 914–32. https://doi.org/10.6004/jnccn.2011.0075.Full Text Link to Item
-
Hirsch, Bradford R., and Gary H. Lyman. “Biosimilars: are they ready for primetime in the United States?” J Natl Compr Canc Netw 9, no. 8 (August 1, 2011): 934–42. https://doi.org/10.6004/jnccn.2011.0076.Full Text Link to Item
-
Lyman, Gary H., and David C. Dale. “Long-term outcomes of myeloid growth factor treatment.” J Natl Compr Canc Netw 9, no. 8 (August 1, 2011): 945–52. https://doi.org/10.6004/jnccn.2011.0077.Full Text Link to Item
-
Rajan, Suja S., Gary H. Lyman, Sally C. Stearns, and William R. Carpenter. “Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.” Med Care 49, no. 7 (July 2011): 649–57. https://doi.org/10.1097/MLR.0b013e318215c42e.Full Text Link to Item
-
Kuderer, Nicole M., and Gary H. Lyman. “Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.” J Natl Cancer Inst 103, no. 12 (June 22, 2011): 910–13. https://doi.org/10.1093/jnci/djr195.Full Text Link to Item
-
Rajan, Suja S., Gary H. Lyman, William R. Carpenter, and Sally C. Stearns. “Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.” Breast Cancer Res Treat 127, no. 2 (June 2011): 511–20. https://doi.org/10.1007/s10549-010-1216-1.Full Text Link to Item
-
Hurwitz, Herbert I., Leonard B. Saltz, Eric Van Cutsem, James Cassidy, Jonas Wiedemann, Florin Sirzén, Gary H. Lyman, and Ulrich-Peter Rohr. “Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.” J Clin Oncol 29, no. 13 (May 1, 2011): 1757–64. https://doi.org/10.1200/JCO.2010.32.3220.Full Text Link to Item
-
Lyman, Gary H., Nicole M. Kuderer, Jeffrey Crawford, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski, and David C. Dale. “Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.” Cancer 117, no. 9 (May 1, 2011): 1917–27. https://doi.org/10.1002/cncr.25691.Full Text Link to Item
-
Valsecchi, Matias E., Damian Silbermins, Nicole de Rosa, Sandra L. Wong, and Gary H. Lyman. “Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis.” J Clin Oncol 29, no. 11 (April 10, 2011): 1479–87. https://doi.org/10.1200/JCO.2010.33.1884.Full Text Link to Item
-
Lyman, Gary H. “Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.” Cancer 117, no. 7 (April 1, 2011): 1334–49. https://doi.org/10.1002/cncr.25714.Full Text Link to Item
-
Hirsch, Bradford R., and Gary H. Lyman. “Breast cancer screening with mammography.” Curr Oncol Rep 13, no. 1 (February 2011): 63–70. https://doi.org/10.1007/s11912-010-0142-z.Full Text Link to Item
-
Kuderer, N. M., and G. H. Lyman. “Erratum: Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy (Journal of the National Cancer Institute (2011) 103:12 (910-913)).” Journal of the National Cancer Institute 103, no. 16 (2011): 1278-. https://doi.org/10.1093/jnci/djr264.Full Text
-
Lyman, G. H., and D. C. Dale. “Cancer Treatment and Research: Preface.” Cancer Treatment and Research 157 (2011): vii–ix. https://doi.org/10.1007/978-1-4419-7073-2.Full Text
-
Lyman, Gary H. “Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines.” J Oncol Pract 7, no. 1 (January 2011): 17–18. https://doi.org/10.1200/JOP.2010.000200.Full Text Link to Item
-
Lyman, Gary H. “A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.” Curr Opin Hematol 18, no. 1 (January 2011): 1–10. https://doi.org/10.1097/MOH.0b013e328340dc51.Full Text Link to Item
-
Aapro, M. S., J. Bohlius, D. A. Cameron, Lissandra Dal Lago, J Peter Donnelly, N. Kearney, G. H. Lyman, et al. “2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.” Eur J Cancer 47, no. 1 (January 2011): 8–32. https://doi.org/10.1016/j.ejca.2010.10.013.Full Text Link to Item
-
Eldar-Lissai, Adi, and Gary H. Lyman. “The economics of the hematopoietic growth factors.” Cancer Treat Res 157 (2011): 403–18. https://doi.org/10.1007/978-1-4419-7073-2_22.Full Text Link to Item
-
Lyman, Gary H. “The myeloid growth factors.” Cancer Treat Res 157 (2011): 109–25. https://doi.org/10.1007/978-1-4419-7073-2_7.Full Text Link to Item
-
Lyman, Gary H., and David C. Dale. “Introduction to the hematopoietic growth factors.” Cancer Treat Res 157 (2011): 3–10. https://doi.org/10.1007/978-1-4419-7073-2_1.Full Text Link to Item
-
Lyman, Gary H., and Jessica Malone Kleiner. “Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.” Cancer Treat Res 157 (2011): 145–65. https://doi.org/10.1007/978-1-4419-7073-2_9.Full Text Link to Item
-
Lyman, Gary H., and Nicole M. Kuderer. “Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome.” Cancer Treat Res 157 (2011): 167–78. https://doi.org/10.1007/978-1-4419-7073-2_10.Full Text Link to Item
-
Kuderer, N. M., and G. H. Lyman. “Response.” Journal of the National Cancer Institute 103, no. 24 (December 21, 2010): 1901–3. https://doi.org/10.1093/jnci/djr440.Full Text
-
Kuderer, N. M., D. C. Dale, J. Crawford, and G. H. Lyman. “Reply to N. Lathia et al.” Journal of Clinical Oncology 28, no. 36 (December 20, 2010). https://doi.org/10.1200/JCO.2010.30.5607.Full Text
-
Hamilton, Erika P., Gary H. Lyman, and Jeffrey Peppercorn. “Availability of experimental therapy outside oncology randomized clinical trials in the United States.” J Clin Oncol 28, no. 34 (December 1, 2010): 5067–73. https://doi.org/10.1200/JCO.2010.28.6567.Full Text Link to Item
-
Lyman, Gary H., Shannon L. Michels, Matthew W. Reynolds, Rich Barron, Karen Smoyer Tomic, and Jingbo Yu. “Risk of mortality in patients with cancer who experience febrile neutropenia.” Cancer 116, no. 23 (December 1, 2010): 5555–63. https://doi.org/10.1002/cncr.25332.Full Text Link to Item
-
Tang, Ping, Jianmin Wang, David G. Hicks, Xi Wang, Linda Schiffhauer, Loralee McMahon, Qi Yang, et al. “A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.” Cancer Invest 28, no. 9 (November 2010): 978–82. https://doi.org/10.3109/07357907.2010.496754.Full Text Link to Item
-
Schwenkglenks, Matthias, Ruth Pettengell, Thomas D. Szucs, Eva Culakova, and Gary H. Lyman. “Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.” J Hematol Oncol 3 (August 19, 2010): 27. https://doi.org/10.1186/1756-8722-3-27.Full Text Open Access Copy Link to Item
-
Connolly, Gregory C., Alok A. Khorana, Nicole M. Kuderer, Eva Culakova, Charles W. Francis, and Gary H. Lyman. “Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.” Thromb Res 126, no. 2 (August 2010): 113–18. https://doi.org/10.1016/j.thromres.2010.05.012.Full Text Link to Item
-
Hornberger, John, Gary H. Lyman, and Rebecca Chien. “Economic implications of 21-gene recurrence score assay: US multicenter experience.” J Clin Oncol 28, no. 22 (August 1, 2010): e382. https://doi.org/10.1200/JCO.2010.28.8944.Full Text Link to Item
-
Lyman, Gary H., David C. Dale, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski, Nicole M. Kuderer, and Jeffrey Crawford. “Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.” J Clin Oncol 28, no. 17 (June 10, 2010): 2914–24. https://doi.org/10.1200/JCO.2009.25.8723.Full Text Link to Item
-
Aapro, Matti, Matthias Schwenkglenks, Gary H. Lyman, Antonio Lopez Pousa, Susan Lawrinson, Tomas Skacel, Pamela Bacon, and Gunter von Minckwitz. “Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.” Crit Rev Oncol Hematol 74, no. 3 (June 2010): 203–10. https://doi.org/10.1016/j.critrevonc.2009.06.004.Full Text Link to Item
-
Herold, Christina I., Benjamin Djulbegovic, Iztok Hozo, and Gary H. Lyman. “Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.” Breast Cancer Res Treat 121, no. 3 (June 2010): 771–76. https://doi.org/10.1007/s10549-009-0564-1.Full Text Link to Item
-
Lyman, Gary H., and Bradford Hirsch. “Comparative effectiveness research and genomic personalized medicine.” Per Med 7, no. 3 (May 2010): 223–27. https://doi.org/10.2217/pme.10.18.Full Text Link to Item
-
Lyman, Gary H., and Kenneth V. I. Rolston. “How we treat febrile neutropenia in patients receiving cancer chemotherapy.” J Oncol Pract 6, no. 3 (May 2010): 149–52. https://doi.org/10.1200/JOP.091092.Full Text Link to Item
-
Lyman, Gary H., Nicole M. Kuderer, and Nicole M. American Society of Clinical Oncology. “Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines.” Thromb Res 125 Suppl 2 (April 2010): S120–27. https://doi.org/10.1016/S0049-3848(10)70029-3.Full Text Link to Item
-
Lyman, Gary H. “Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?” Cancer Invest 28, no. 3 (March 2010): 217–19. https://doi.org/10.3109/07357901003640404.Full Text Link to Item
-
Lyman, Gary H. “Breast cancer screening: science, society and common sense.” Cancer Invest 28, no. 1 (January 2010): 1–6. https://doi.org/10.3109/07357900903517001.Full Text Link to Item
-
Lyman, Gary H. “Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.” Cancer 115, no. 24 (December 15, 2009): 5637–50. https://doi.org/10.1002/cncr.24665.Full Text Link to Item
-
Cosler, Leon E., and Gary H. Lyman. “Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.” Cancer Invest 27, no. 10 (December 2009): 953–59. https://doi.org/10.3109/07357900903275217.Full Text Link to Item
-
Shayne, Michelle, Eva Culakova, Debra Wolff, Marek S. Poniewierski, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.” Cancer 115, no. 22 (November 15, 2009): 5319–28. https://doi.org/10.1002/cncr.24560.Full Text Link to Item
-
Lyman, Gary H., and Jeffrey Peppercorn. “Isolated tumor cells in breast cancer.” N Engl J Med 361, no. 20 (November 12, 2009): 1994. https://doi.org/10.1056/NEJMc091861.Full Text Link to Item
-
Bevers, Therese B., Benjamin O. Anderson, Ermelinda Bonaccio, Saundra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, et al. “NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.” J Natl Compr Canc Netw 7, no. 10 (November 2009): 1060–96. https://doi.org/10.6004/jnccn.2009.0070.Full Text Link to Item
-
Kuderer, Nicole M., and Gary H. Lyman. “Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer.” Cancer Invest 27, no. 9 (November 2009): 885–90. https://doi.org/10.3109/07357900903275142.Full Text Link to Item
-
Khorana, Alok A., Michael B. Streiff, Dominique Farge, Mario Mandala, Philippe Debourdeau, Francis Cajfinger, Michel Marty, Anna Falanga, and Gary H. Lyman. “Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.” J Clin Oncol 27, no. 29 (October 10, 2009): 4919–26. https://doi.org/10.1200/JCO.2009.22.3214.Full Text Link to Item
-
Lyman, Gary H., and Alok A. Khorana. “Cancer, clots and consensus: new understanding of an old problem.” J Clin Oncol 27, no. 29 (October 10, 2009): 4821–26. https://doi.org/10.1200/JCO.2009.22.3032.Full Text Link to Item
-
Lyman, G. H. “Prevention of venous thromboembolism in the non-surgical patient with cancer.” Clinical Advances in Hematology and Oncology 7, no. 10 (October 1, 2009): 7–9.
-
Lyman, G. H. “The road to romiplostim approval and beyond.” Oncology (Williston Park, N.Y.) 23, no. 8 (July 1, 2009).
-
Lyman, Gary H. “The road to romiplostim approval and beyond.” Oncology (Williston Park) 23, no. 8 (July 2009): 709–15.Link to Item
-
Lyman, Gary H. “Preventing venous thromboembolism in cancer patients: can we do better?” J Oncol Pract 5, no. 4 (July 2009): 165–66. https://doi.org/10.1200/JOP.0941501.Full Text Link to Item
-
Lyman, Gary H. “Comparative effectiveness research in oncology: the need for clarity, transparency and vision.” Cancer Invest 27, no. 6 (July 2009): 593–97. https://doi.org/10.1080/07357900903109952.Full Text Link to Item
-
Madeb, Ralph, Dragan Golijanin, Katia Noyes, Susan Fisher, Judith J. Stephenson, Stacey R. Long, Joy Knopf, Gary H. Lyman, and Edward M. Messing. “Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.” Cancer 115, no. 12 (June 15, 2009): 2660–70. https://doi.org/10.1002/cncr.24311.Full Text Link to Item
-
Lyman, Gary H., Alok A. Khorana, Nicole M. Kuderer, and Agnes Y. Lee. “Cancer and thrombosis: back to the future renewed interest in an old problem.” Cancer Invest 27, no. 5 (June 2009): 472–73. https://doi.org/10.1080/07357900902996441.Full Text Link to Item
-
Lyman, Gary H., Anjana Lalla, Richard L. Barron, and Robert W. Dubois. “Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.” Clin Ther 31, no. 5 (May 2009): 1092–1104. https://doi.org/10.1016/j.clinthera.2009.05.003.Full Text Link to Item
-
Lyman, Gary H., Nicole M. Kuderer, and Stephen J. Freedland. “Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.” J Natl Cancer Inst 101, no. 8 (April 15, 2009): 543–45. https://doi.org/10.1093/jnci/djp060.Full Text Link to Item
-
Minckwitz, G. von, M. Schwenkglenks, T. Skacel, G. H. Lyman, A Lopez Pousa, P. Bacon, V. Easton, and M. S. Aapro. “Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.” Eur J Cancer 45, no. 4 (March 2009): 608–17. https://doi.org/10.1016/j.ejca.2008.11.021.Full Text Link to Item
-
Lyman, Gary, Anjana Lalla, Richard Barron, and Robert W. Dubois. “Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.” Curr Med Res Opin 25, no. 2 (February 2009): 401–11. https://doi.org/10.1185/03007990802636817.Full Text Link to Item
-
Crawford, Jeffrey, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, et al. “Myeloid growth factors.” J Natl Compr Canc Netw 7, no. 1 (January 2009): 64–83. https://doi.org/10.6004/jnccn.2009.0006.Full Text Link to Item
-
Tang, P., J. Wang, D. G. Hicks, X. Wang, L. Schiffhauer, M. Shayne, A. Huston, K. Skinner, J. Griggs, and G. Lyman. “The Relationship between Oncotype DX Recurrence Score, Clinicopathological Factors, and Molecular Classification in Breast Cancer.” Laboratory Investigation 89 (January 1, 2009): 72A-72A.Link to Item
-
Lyman, Gary H. “Impact of chemotherapy dose intensity on cancer patient outcomes.” J Natl Compr Canc Netw 7, no. 1 (January 2009): 99–108. https://doi.org/10.6004/jnccn.2009.0009.Full Text Link to Item
-
Ramsey, Scott D., Zhimei Liu, Rob Boer, Sean D. Sullivan, Jennifer Malin, Quan V. Doan, Robert W. Dubois, and Gary H. Lyman. “Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.” Value Health 12, no. 2 (2009): 217–25. https://doi.org/10.1111/j.1524-4733.2008.00434.x.Full Text Link to Item
-
Horan, John T., Todd A. Alonzo, Gary H. Lyman, Robert B. Gerbing, Beverly J. Lange, Yaddanapudi Ravindranath, David Becton, Franklin O. Smith, William G. Woods, and William G. Children’s Oncology Group. “Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.” J Clin Oncol 26, no. 35 (December 10, 2008): 5797–5801. https://doi.org/10.1200/JCO.2007.13.5244.Full Text Link to Item
-
Khorana, Alok A., Charles W. Francis, Neil Blumberg, Eva Culakova, Majed A. Refaai, and Gary H. Lyman. “Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.” Arch Intern Med 168, no. 21 (November 24, 2008): 2377–81. https://doi.org/10.1001/archinte.168.21.2377.Full Text Link to Item
-
Ferro, Salvatore A., Brian S. Myer, Debra A. Wolff, Marek S. Poniewierski, Eva Culakova, Leon E. Cosler, Sarah L. Scarpace, Alok A. Khorana, and Gary H. Lyman. “Variation in the cost of medications for the treatment of colorectal cancer.” Am J Manag Care 14, no. 11 (November 2008): 717–25.Link to Item
-
Greenberg, Peter L., Eyal Attar, Minoo Battiwalla, John M. Bennett, Clara D. Bloomfield, Carlos M. DeCastro, H Joachim Deeg, et al. “Myelodysplastic syndromes.” J Natl Compr Canc Netw 6, no. 9 (October 2008): 902–26.Link to Item
-
Khorana, A. A., C. W. Francis, A. Falanga, and G. H. Lyman. “In reply.” Journal of Clinical Oncology 26, no. 11 (September 15, 2008): 1906–7. https://doi.org/10.1200/JCO.2008.16.0887.Full Text
-
Lyman, Gary H. “ASCO Clinical Practice Guidelines: Past, Present and Future.” J Oncol Pract 4, no. 5 (September 2008): 236–37. https://doi.org/10.1200/JOP.0851501.Full Text Link to Item
-
Lyman, Gary H. “Journal of oncology practice in transition.” J Oncol Pract 4, no. 5 (September 2008): 213. https://doi.org/10.1200/JOP.0850501.Full Text Link to Item
-
Constine, Louis S., Nancy Tarbell, Melissa M. Hudson, Cindy Schwartz, Susan G. Fisher, Ann G. Muhs, Swati K. Basu, et al. “Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.” Int J Radiat Oncol Biol Phys 72, no. 1 (September 1, 2008): 24–33. https://doi.org/10.1016/j.ijrobp.2008.04.067.Full Text Link to Item
-
Somerfield, Mark R., Kaitlin Einhaus, Karen L. Hagerty, Melissa C. Brouwers, Jerome Seidenfeld, Gary H. Lyman, and Gary H. American Society of Clinical Oncology. “American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.” J Clin Oncol 26, no. 24 (August 20, 2008): 4022–26. https://doi.org/10.1200/JCO.2008.17.7139.Full Text Link to Item
-
Khorana, A. A., C. W. Francis, and G. H. Lyman. “Reply to frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.” Cancer 113, no. 1 (July 1, 2008): 224. https://doi.org/10.1002/cncr.23525.Full Text
-
Lyman, Gary H. “Caring for the elderly cancer patient: training the next generation of oncologists.” J Oncol Pract 4, no. 4 (July 2008): 193–94. https://doi.org/10.1200/JOP.0841503.Full Text Link to Item
-
Khorana, Alok A., Nicole M. Kuderer, Eva Culakova, Gary H. Lyman, and Charles W. Francis. “Development and validation of a predictive model for chemotherapy-associated thrombosis.” Blood 111, no. 10 (May 15, 2008): 4902–7. https://doi.org/10.1182/blood-2007-10-116327.Full Text Link to Item
-
Lyman, Gary H. “Undertreatment of cancer patients with chemotherapy is a global concern.” J Oncol Pract 4, no. 3 (May 2008): 114–15. https://doi.org/10.1200/JOP.0831502.Full Text Link to Item
-
Lyman, Gary H., and Robert S. Hauser. “Optimal cancer care across the spectrum of life and disease.” Am J Manag Care 14, no. 5 (May 2008): 262–64.Link to Item
-
Acharya, Chaitanya R., David S. Hsu, Carey K. Anders, Ariel Anguiano, Kelly H. Salter, Kelli S. Walters, Richard C. Redman, et al. “Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.” Jama 299, no. 13 (April 2, 2008): 1574–87. https://doi.org/10.1001/jama.299.13.1574.Full Text Link to Item
-
Hanley, Krisztina, Jianmin Wang, Patricia Bourne, Qi Yang, Allen C. Gao, Gary Lyman, and Ping Tang. “Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.” Hum Pathol 39, no. 3 (March 2008): 386–92. https://doi.org/10.1016/j.humpath.2007.07.007.Full Text Link to Item
-
Fletcher, James W., Benjamin Djulbegovic, Heloisa P. Soares, Barry A. Siegel, Val J. Lowe, Gary H. Lyman, R Edward Coleman, et al. “Recommendations on the use of 18F-FDG PET in oncology.” J Nucl Med 49, no. 3 (March 2008): 480–508. https://doi.org/10.2967/jnumed.107.047787.Full Text Link to Item
-
Crawford, Jeffrey, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman. “Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.” J Natl Compr Canc Netw 6, no. 2 (February 2008): 109–18. https://doi.org/10.6004/jnccn.2008.0012.Full Text Link to Item
-
Lyman, G. H. “Obesity is not Associated With Increased Myelosuppression in Patients Receiving Chemotherapy for Breast Cancer.” Breast Diseases 19, no. 1 (2008): 88–89. https://doi.org/10.1016/S1043-321X(08)80062-8.Full Text
-
Eldar-Lissai, Adi, Leon E. Cosler, Eva Culakova, and Gary H. Lyman. “Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.” Value Health 11, no. 2 (2008): 172–79. https://doi.org/10.1111/j.1524-4733.2007.00242.x.Full Text Link to Item
-
Djulbegovic, Benjamin, Iztok Hozo, and Gary H. Lyman. “Estimating net benefits and harms of screening mammography in women age 40 to 49 years.” Ann Intern Med 147, no. 12 (December 18, 2007): 882. https://doi.org/10.7326/0003-4819-147-12-200712180-00010.Full Text Link to Item
-
Lyman, Gary H., Alok A. Khorana, Anna Falanga, Daniel Clarke-Pearson, Christopher Flowers, Mohammad Jahanzeb, Ajay Kakkar, et al. “American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.” J Clin Oncol 25, no. 34 (December 1, 2007): 5490–5505. https://doi.org/10.1200/JCO.2007.14.1283.Full Text Link to Item
-
Khorana, Alok A., Charles W. Francis, Eva Culakova, Nicole M. Kuderer, and Gary H. Lyman. “Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.” Cancer 110, no. 10 (November 15, 2007): 2339–46. https://doi.org/10.1002/cncr.23062.Full Text Link to Item
-
Lyman, Gary H. “ASCO Clinical Practice Guidelines and Beyond.” J Oncol Pract 3, no. 6 (November 2007): 330–31. https://doi.org/10.1200/JOP.0761501.Full Text Link to Item
-
Huston, Alissa, and Gary H. Lyman. “Agents under investigation for the treatment and prevention of neutropenia.” Expert Opin Investig Drugs 16, no. 11 (November 2007): 1831–40. https://doi.org/10.1517/13543784.16.11.1831.Full Text Link to Item
-
Shayne, Michelle, Eva Culakova, Marek S. Poniewierski, Debra Wolff, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.” Cancer 110, no. 7 (October 1, 2007): 1611–20. https://doi.org/10.1002/cncr.22939.Full Text Link to Item
-
Pinto, Lionel, Zhimei Liu, Quan Doan, Myriam Bernal, Robert Dubois, and Gary Lyman. “Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.” Curr Med Res Opin 23, no. 9 (September 2007): 2283–95. https://doi.org/10.1185/030079907X219599.Full Text Link to Item
-
Kuderer, Nicole M., Alok A. Khorana, Gary H. Lyman, and Charles W. Francis. “A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.” Cancer 110, no. 5 (September 1, 2007): 1149–61. https://doi.org/10.1002/cncr.22892.Full Text Link to Item
-
Kuderer, Nicole M., David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.” J Clin Oncol 25, no. 21 (July 20, 2007): 3158–67. https://doi.org/10.1200/JCO.2006.08.8823.Full Text Link to Item
-
Lyman, Gary H. “Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer.” J Oncol Pract 3, no. 4 (July 2007): 187–88. https://doi.org/10.1200/JOP.0741502.Full Text Link to Item
-
Lyman, Gary H., and Michelle Shayne. “Granulocyte colony-stimulating factors: finding the right indication.” Curr Opin Oncol 19, no. 4 (July 2007): 299–307. https://doi.org/10.1097/CCO.0b013e3281a3c0ba.Full Text Link to Item
-
Griggs, Jennifer J., Eva Culakova, Melony E. S. Sorbero, Marek S. Poniewierski, Debra A. Wolff, Jeffrey Crawford, David C. Dale, and Gary H. Lyman. “Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.” J Clin Oncol 25, no. 18 (June 20, 2007): 2522–27. https://doi.org/10.1200/JCO.2006.10.2749.Full Text Link to Item
-
Griggs, J. J., E. Culakova, M. E. S. Sorbero, and G. H. Lyman. “In reply [4].” Journal of Clinical Oncology 25, no. 16 (June 1, 2007): 2332. https://doi.org/10.1200/JCO.2007.11.5881.Full Text
-
Lyman, Gary H. “Economics of cancer care.” J Oncol Pract 3, no. 3 (May 2007): 113–14. https://doi.org/10.1200/JOP.0731501.Full Text Link to Item
-
Blumberg, Neil, Hongwei Zhao, Hongkun Wang, Susan Messing, Joanna M. Heal, and Gary H. Lyman. “The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.” Transfusion 47, no. 4 (April 2007): 573–81. https://doi.org/10.1111/j.1537-2995.2007.01158.x.Full Text Link to Item
-
Lyman, Gary H., Leon E. Cosler, Nicole M. Kuderer, and John Hornberger. “Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.” Cancer 109, no. 6 (March 15, 2007): 1011–18. https://doi.org/10.1002/cncr.22506.Full Text Link to Item
-
Khorana, A. A., C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman. “Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.” J Thromb Haemost 5, no. 3 (March 2007): 632–34. https://doi.org/10.1111/j.1538-7836.2007.02374.x.Full Text Link to Item
-
Crawford, Jeffrey, Betsy Althaus, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, et al. “Myeloid growth factors. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 5, no. 2 (February 2007): 188–202. https://doi.org/10.6004/jnccn.2007.0019.Full Text Link to Item
-
Lyman, Gary H., and Jessica Malone Kleiner. “Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.” J Natl Compr Canc Netw 5, no. 2 (February 2007): 217–28. https://doi.org/10.6004/jnccn.2007.0021.Full Text Link to Item
-
Tang, Ping, Steven I. Hajdu, and Gary H. Lyman. “Ductal carcinoma in situ: a review of recent advances.” Curr Opin Obstet Gynecol 19, no. 1 (February 2007): 63–67. https://doi.org/10.1097/GCO.0b013e3280114a3a.Full Text Link to Item
-
Griggs, Jennifer J., Eva Culakova, Melony E. S. Sorbero, Michelle van Ryn, Marek S. Poniewierski, Debra A. Wolff, Jeffrey Crawford, David C. Dale, and Gary H. Lyman. “Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.” J Clin Oncol 25, no. 3 (January 20, 2007): 277–84. https://doi.org/10.1200/JCO.2006.08.3063.Full Text Link to Item
-
Cosler, Leon E., Adi Eldar-Lissai, Eva Culakova, Nicole M. Kuderer, David Dale, Jeffrey Crawford, and Gary H. Lyman. “Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.” Pharmacoeconomics 25, no. 4 (2007): 343–51. https://doi.org/10.2165/00019053-200725040-00006.Full Text Link to Item
-
Lyman, G. H. “Advances in Cancer Investigation.” Cancer Investigation 25, no. 7 (2007): 515–16. https://doi.org/10.1080/07357900701709409.Full Text
-
Lyman, G. H. “The moving target of cancer care costs.” Oncology 21, no. 7 (2007): 862+866.
-
Lyman, G. H., A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, et al. “American Society of Clinical Oncology 2007 clinical practice guideline recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.” Journal of Oncology Practice 3, no. 6 (2007): 326–29. https://doi.org/10.1200/JOP.0768502.Full Text
-
Pettengell, R., T. Skacel, M. Aapro, U. Duehrsen, V. Easton, and G. Lyman. “Pegfilgrastim provides effective primary prophylaxis against febrile neutropenia in patients with non-Hodgkin's lymphoma undergoing chemotherapy: Initial results from an integrated analysis - The Neulasta Versus Current Neutropenia Management Practice (NEUCUP) Project.” Journal of Supportive Oncology 5, no. 4 SUPPL. 2 (2007): 40–41.
-
Djulbegovic, Benjamin, and Gary H. Lyman. “Screening mammography at 40-49 years: regret or no regret?” Lancet 368, no. 9552 (December 9, 2006): 2035–37. https://doi.org/10.1016/S0140-6736(06)69816-4.Full Text Link to Item
-
Lyman, Gary H. “Chemotherapy dose intensity and quality cancer care.” Oncology (Williston Park) 20, no. 14 Suppl 9 (December 2006): 16–25.Link to Item
-
Lyman, Gary H., and Nicole M. Kuderer. “Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis.” Clin Breast Cancer 7, no. 5 (December 2006): 372–79. https://doi.org/10.3816/CBC.2006.n.053.Full Text Link to Item
-
Shayne, Michelle, Jeffrey Crawford, David C. Dale, Eva Culakova, Gary H. Lyman, and Gary H. ANC Study Group. “Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.” Breast Cancer Res Treat 100, no. 3 (December 2006): 255–62. https://doi.org/10.1007/s10549-006-9254-4.Full Text Link to Item
-
Aapro, M. S., D. A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, M. Ellis, N. Kearney, et al. “EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.” Eur J Cancer 42, no. 15 (October 2006): 2433–53. https://doi.org/10.1016/j.ejca.2006.05.002.Full Text Link to Item
-
Lyman, Gary H. “Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.” Oncology (Williston Park) 20, no. 8 Suppl 6 (July 2006): 16–20.Link to Item
-
Smith, Thomas J., James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, et al. “2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.” J Clin Oncol 24, no. 19 (July 1, 2006): 3187–3205. https://doi.org/10.1200/JCO.2006.06.4451.Full Text Link to Item
-
Komrokji, Rami S., Nikhil P. Uppal, Alok A. Khorana, Gary H. Lyman, Karen L. Kaplan, Richard I. Fisher, and Charles W. Francis. “Venous thromboembolism in patients with diffuse large B-cell lymphoma.” Leuk Lymphoma 47, no. 6 (June 2006): 1029–33. https://doi.org/10.1080/10428190600560991.Full Text Link to Item
-
Wittman, Brenda, John Horan, and Gary H. Lyman. “Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.” Cancer Treat Rev 32, no. 4 (June 2006): 289–303. https://doi.org/10.1016/j.ctrv.2006.03.002.Full Text Link to Item
-
Kuderer, Nicole M., David C. Dale, Jeffrey Crawford, Leon E. Cosler, and Gary H. Lyman. “Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.” Cancer 106, no. 10 (May 15, 2006): 2258–66. https://doi.org/10.1002/cncr.21847.Full Text Link to Item
-
Lyman, Gary H. “Withholding antibiotics from patients with febrile neutropenia.” J Clin Oncol 24, no. 7 (March 1, 2006): 1221–22. https://doi.org/10.1200/JCO.2005.04.7670.Full Text Link to Item
-
Khorana, Alok A., Charles W. Francis, Eva Culakova, Richard I. Fisher, Nicole M. Kuderer, and Gary H. Lyman. “Thromboembolism in hospitalized neutropenic cancer patients.” J Clin Oncol 24, no. 3 (January 20, 2006): 484–90. https://doi.org/10.1200/JCO.2005.03.8877.Full Text Link to Item
-
Chang, Stella, Stacey R. Long, Lucie Kutikova, Lee Bowman, William H. Crown, and Gary H. Lyman. “Burden of pancreatic cancer and disease progression: economic analysis in the US.” Oncology 70, no. 1 (2006): 71–80. https://doi.org/10.1159/000091312.Full Text Link to Item
-
Kuthiala, S. S., G. H. Lyman, and O. F. Ballester. “Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience.” Bone Marrow Transplant 37, no. 2 (January 2006): 219–21. https://doi.org/10.1038/sj.bmt.1705230.Full Text Link to Item
-
Lyman, G. H., and J. Glaspy. “Examining the benefits of early erythropoietic intervention in patients with chemotherapy-induced anemia.” American Journal of Oncology Review 5, no. 4 (2006): 236–41.
-
Lyman, Gale. “Serendipities leading to private practice.” Beginnings 26, no. 2 (2006): 20–21.Link to Item
-
Lyman, Gary H. “Risks and consequences of chemotherapy-induced neutropenia.” Clin Cornerstone 8 Suppl 5 (2006): S12–18. https://doi.org/10.1016/s1098-3597(06)80054-2.Full Text Link to Item
-
Kim, Theodore, Armando E. Giuliano, and Gary H. Lyman. “Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.” Cancer 106, no. 1 (January 1, 2006): 4–16. https://doi.org/10.1002/cncr.21568.Full Text Link to Item
-
Lyman, Gary H., and John Glaspy. “Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review.” Cancer 106, no. 1 (January 1, 2006): 223–33. https://doi.org/10.1002/cncr.21570.Full Text Link to Item
-
Khorana, Alok A., Charles W. Francis, Eva Culakova, and Gary H. Lyman. “Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.” Cancer 104, no. 12 (December 15, 2005): 2822–29. https://doi.org/10.1002/cncr.21496.Full Text Link to Item
-
Lyman, Gary H. “Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.” Expert Opin Biol Ther 5, no. 12 (December 2005): 1635–46. https://doi.org/10.1517/14712598.5.12.1635.Full Text Link to Item
-
Lyman, Gary H., and Benjamin Djulbegovic. “The challenge of systematic reviews of diagnostic and staging studies in cancer.” Cancer Treat Rev 31, no. 8 (December 2005): 628–39. https://doi.org/10.1016/j.ctrv.2005.07.001.Full Text Link to Item
-
Basu, Swati K., Isabel D. Fernandez, Susan G. Fisher, Barbara L. Asselin, and Gary H. Lyman. “Length of stay and mortality associated with febrile neutropenia among children with cancer.” J Clin Oncol 23, no. 31 (November 1, 2005): 7958–66. https://doi.org/10.1200/JCO.2005.01.6378.Full Text Link to Item
-
Wolff, D., E. Culakova, M. S. Poniewierski, G. H. Lyman, D. C. Dale, and J. Crawford. “Predictors of chemotherapy-induced neutropenia and its complications: Results from a prospective nationwide registry.” Journal of Supportive Oncology 3, no. 6 SUPPL. 4 (November 1, 2005): 24–25.
-
Lyman, Gary H., Armando E. Giuliano, Mark R. Somerfield, Al B. Benson, Diane C. Bodurka, Harold J. Burstein, Alistair J. Cochran, et al. “American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.” J Clin Oncol 23, no. 30 (October 20, 2005): 7703–20. https://doi.org/10.1200/JCO.2005.08.001.Full Text Link to Item
-
Lyman, Gary H. “Time is money for both the healthy and the sick.” Med Care 43, no. 7 (July 2005): 637–39. https://doi.org/10.1097/01.mlr.0000168840.24299.29.Full Text Link to Item
-
Crawford, Jeffrey, Betsy Althaus, James Armitage, Douglas W. Blayney, Spero Cataland, David C. Dale, George D. Demetri, et al. “Myeloid growth factors clinical practice guidelines in oncology.” J Natl Compr Canc Netw 3, no. 4 (July 2005): 540–55. https://doi.org/10.6004/jnccn.2005.0030.Full Text Link to Item
-
Lyman, Gary H. “Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.” J Natl Compr Canc Netw 3, no. 4 (July 2005): 557–71. https://doi.org/10.6004/jnccn.2005.0031.Full Text Link to Item
-
Clark, Otavio A. C., Gary H. Lyman, Aldemar A. Castro, Luciana G. O. Clark, and Benjamin Djulbegovic. “Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.” J Clin Oncol 23, no. 18 (June 20, 2005): 4198–4214. https://doi.org/10.1200/JCO.2005.05.645.Full Text Link to Item
-
Griggs, Jennifer J., Melony E. S. Sorbero, and Gary H. Lyman. “Undertreatment of obese women receiving breast cancer chemotherapy.” Arch Intern Med 165, no. 11 (June 13, 2005): 1267–73. https://doi.org/10.1001/archinte.165.11.1267.Full Text Link to Item
-
Hozo, Iztok, Benjamin Djulbegovic, Otavio Clark, and Gary H. Lyman. “Use of re-randomized data in meta-analysis.” Bmc Med Res Methodol 5 (May 10, 2005): 17. https://doi.org/10.1186/1471-2288-5-17.Full Text Link to Item
-
Hornberger, John, Leon E. Cosler, and Gary H. Lyman. “Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.” Am J Manag Care 11, no. 5 (May 2005): 313–24.Link to Item
-
Lyman, Gary H., and Nicole M. Kuderer. “The strengths and limitations of meta-analyses based on aggregate data.” Bmc Med Res Methodol 5 (April 25, 2005): 14. https://doi.org/10.1186/1471-2288-5-14.Full Text Link to Item
-
Lyman, Gary H., and Nicole M. Kuderer. “A primer in prognostic and predictive models: development and validation of neutropenia risk models.” Support Cancer Ther 2, no. 3 (April 1, 2005): 168–75. https://doi.org/10.3816/SCT.2005.n.009.Full Text Link to Item
-
Crawford, J., D. Wolff, E. Culakova, M. S. Poniewierski, C. Selby, D. Dale, and G. H. Lyman. “First-cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study.” Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (March 1, 2005): 52–53.
-
Wolff, D. A., J. Crawford, D. C. Dale, M. S. Poniewierski, and G. H. Lyman. “Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systemic chemotherapy.” Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (March 1, 2005): 56–57.
-
Balducci, Lodovico, Cheryl L. Hardy, and Gary H. Lyman. “Hemopoiesis and aging.” Cancer Treat Res 124 (2005): 109–34. https://doi.org/10.1007/0-387-23962-6_6.Full Text Link to Item
-
Berndt, Ernst, William Crown, Joel Kallich, Stacey Long, Xue Song, and Gary H. Lyman. “The impact of anaemia and its treatment on employee disability and medical costs.” Pharmacoeconomics 23, no. 2 (2005): 183–92. https://doi.org/10.2165/00019053-200523020-00009.Full Text Link to Item
-
Clark, O. A. C., G. H. Lyman, and B. Djulbegovic. “In reply [2].” Journal of Clinical Oncology 23, no. 33 (2005): 8537–38. https://doi.org/10.1200/JCO.2005.03.6798.Full Text
-
Hornberger, J., L. E. Cosler, and G. H. Lyman. “Erratum: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer (American Journal of Managed Care (May 2005) 11, 5 (313-324).” American Journal of Managed Care 11, no. 8 (2005): 476-.
-
Lyman, Gary H., and Nicole M. Kuderer. “Moving beyond febrile neutropenia.” Support Cancer Ther 2, no. 2 (January 1, 2005): 95–97. https://doi.org/10.1016/s1543-2912(13)60042-9.Full Text Link to Item
-
Cosler, Leon E., Visaharan Sivasubramaniam, Olayemi Agboola, Jeffrey Crawford, David Dale, and Gary H. Lyman. “Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.” Value Health 8, no. 1 (2005): 47–52. https://doi.org/10.1111/j.1524-4733.2005.03099.x.Full Text Link to Item
-
Eldar-Lissai, A., L. Cosler, and G. H. Lyman. “Economic analysis of prophylactic pegfilgrastim in cancer patients receiving chemotherapy.” Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (2005): 54–55.
-
Lyman, Gary H., Christopher H. Lyman, and Olayemi Agboola. “Risk models for predicting chemotherapy-induced neutropenia.” Oncologist 10, no. 6 (2005): 427–37. https://doi.org/10.1634/theoncologist.10-6-427.Full Text Link to Item
-
Lyman, Gary H., Ernst R. Berndt, Joel D. Kallich, M Haim Erder, William H. Crown, Stacey R. Long, Howard Lee, Xue Song, and Stan N. Finkelstein. “The economic burden of anemia in cancer patients receiving chemotherapy.” Value Health 8, no. 2 (2005): 149–56. https://doi.org/10.1111/j.1524-4733.2005.03089.x.Full Text Link to Item
-
Wolff, Debra, Eva Culakova, Marek S. Poniewierski, Gary H. Lyman, David C. Dale, Jeffrey Crawford, and Jeffrey Awareness of Neutropenia in Chemotherapy Study Group. “Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry.” J Support Oncol 3, no. 6 Suppl 4 (2005): 24–25.Link to Item
-
Komrokji, Rami S., and Gary H. Lyman. “The colony-stimulating factors: use to prevent and treat neutropenia and its complications.” Expert Opin Biol Ther 4, no. 12 (December 2004): 1897–1910. https://doi.org/10.1517/14712598.4.12.1897.Full Text Link to Item
-
Lyman, Gary H., David C. Dale, Jonathan Friedberg, Jeffrey Crawford, and Richard I. Fisher. “Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.” J Clin Oncol 22, no. 21 (November 1, 2004): 4302–11. https://doi.org/10.1200/JCO.2004.03.213.Full Text Link to Item
-
Dubois, Robert W., Lionel A. Pinto, Myriam Bernal, Enkhe Badamgarav, and Gary H. Lyman. “Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature.” Support Cancer Ther 2, no. 1 (October 1, 2004): 34–41. https://doi.org/10.3816/SCT.2004.n.020.Full Text Link to Item
-
Hesketh, Paul J., Diane Batchelor, Mitch Golant, Gary H. Lyman, Nelson Rhodes, and Denise Yardley. “Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.” Support Care Cancer 12, no. 8 (August 2004): 543–49. https://doi.org/10.1007/s00520-003-0562-5.Full Text Link to Item
-
Price, Nancy, Vinay K. Jain, and Gary H. Lyman. “Prophylactic pegfilgrastim significantly reduces febrile neutropenia during moderately myelosuppressive chemotherapy.” Support Cancer Ther 1, no. 4 (July 1, 2004): 207–9. https://doi.org/10.1016/s1543-2912(13)60128-9.Full Text Link to Item
-
Lyman, Gary H., Eva Culakova, and Jennifer Griggs. “Use of antibiotics and risk of cancer.” Jama 291, no. 22 (June 9, 2004): 2700. https://doi.org/10.1001/jama.291.22.2700-a.Full Text Link to Item
-
Shear, Neil H., Donald A. Redelmeier, Jeffrey P. Callen, and Jeffrey P. Ad Hoc Task Force of the American Academy of Dermatology on the Reported Link Between Antibiotic Use and Breast Cancer. “Use of antibiotics and risk of cancer.” Jama 291, no. 22 (June 9, 2004): 2699. https://doi.org/10.1001/jama.291.22.2699-a.Full Text Link to Item
-
Crawford, J., D. C. Dale, and G. H. Lyman. “Erratum: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management (Cancer (2004) 100 (228-237)).” Cancer 100, no. 9 (May 1, 2004): 1993–94. https://doi.org/10.1002/cncr.20218.Full Text
-
Lyman, Gary H., Stephanie J. Green, Peter M. Ravdin, Charles E. Geyer, Christy A. Russell, Stanley P. Balcerzak, G. Thomas Budd, Silvana Martino, and Silvana Southwest Oncology Group Randomized Phase II Study. “A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.” Breast Cancer Res Treat 85, no. 2 (May 2004): 143–50. https://doi.org/10.1023/B:BREA.0000025405.63953.f9.Full Text Link to Item
-
Lyman, G. H., and N. M. Kuderer. “The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.” Crit Rev Oncol Hematol 50, no. 2 (May 2004): 129–46. https://doi.org/10.1016/j.critrevonc.2004.01.001.Full Text Link to Item
-
Cosler, Leon E., Elizabeth A. Calhoun, Olayemi Agboola, and Gary H. Lyman. “Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.” Pharmacotherapy 24, no. 4 (April 2004): 488–94. https://doi.org/10.1592/phco.24.5.488.33360.Full Text Link to Item
-
Crawford, Jeffrey, David C. Dale, and Gary H. Lyman. “Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.” Cancer 100, no. 2 (January 15, 2004): 228–37. https://doi.org/10.1002/cncr.11882.Full Text Link to Item
-
Adams, Jared R., Linda S. Elting, Gary H. Lyman, James N. George, Barry C. Lembersky, James O. Armitage, George D. Demetri, and Charles L. Bennett. “Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.” Am J Med 116, no. 1 (January 1, 2004): 28–34. https://doi.org/10.1016/j.amjmed.2003.06.004.Full Text Link to Item
-
Lyman, Gary H., David C. Dale, and Jeffrey Crawford. “Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.” J Clin Oncol 21, no. 24 (December 15, 2003): 4524–31. https://doi.org/10.1200/JCO.2003.05.002.Full Text Link to Item
-
Lyman, Gary H., Vicki A. Morrison, David C. Dale, Jeffrey Crawford, David J. Delgado, Moshe Fridman, Moshe OPPS Working Group, and Moshe ANC Study Group. “Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.” Leuk Lymphoma 44, no. 12 (December 2003): 2069–76. https://doi.org/10.1080/1042819031000119262.Full Text Link to Item
-
Holmgren, B. “Introduction.” Russian Memoir: History and Literature, December 1, 2003.
-
Lyman, Gary H., and David J. Delgado. “Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.” Cancer 98, no. 11 (December 1, 2003): 2402–9. https://doi.org/10.1002/cncr.11827.Full Text Link to Item
-
Lyman, Gary H. “Introduction. Neutropenia risk models in oncology.” Oncology (Williston Park) 17, no. 11 Suppl 11 (November 2003): 5–7.Link to Item
-
Lyman, Gary H. “Risk assessment in oncology clinical practice. From risk factors to risk models.” Oncology (Williston Park) 17, no. 11 Suppl 11 (November 2003): 8–13.Link to Item
-
Lyman, Gary H., and Nicole M. Kuderer. “Cost effectiveness of myeloid growth factors in cancer chemotherapy.” Curr Hematol Rep 2, no. 6 (November 2003): 471–79.Link to Item
-
Paridaens, R., G. H. Lyman, R. Leonard, J. Crawford, A. Bosly, M. Constenla, C. Jackisch, R. Pettengell, and T. Szucs. “Delivering optimal adjuvant chemotherapy in primary breast cancer: The role of rHuG-CSF.” European Journal of Cancer, Supplement 1, no. 9 (November 1, 2003): 1–12. https://doi.org/10.1016/S1359-6349(03)00082-X.Full Text
-
Lyman, Gary H., and Nicole M. Kuderer. “Epidemiology of febrile neutropenia.” Support Cancer Ther 1, no. 1 (October 1, 2003): 23–35. https://doi.org/10.3816/SCT.2003.n.002.Full Text Link to Item
-
Haithcox, Susan, Carmella R Ramnes, Howard Lee, John Lu, and Gary H. Lyman. “The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study.” Bmc Nurs 2, no. 1 (September 19, 2003): 2. https://doi.org/10.1186/1472-6955-2-2.Full Text Link to Item
-
Horan, J. T., J. L. Liesveld, I. D. Fernandez, G. H. Lyman, G. L. Phillips, N. B. Lerner, and S. G. Fisher. “Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials.” Bone Marrow Transplant 32, no. 3 (August 2003): 293–98. https://doi.org/10.1038/sj.bmt.1704112.Full Text Link to Item
-
Lyman, Gary H. “Balancing the benefits and costs of colony-stimulating factors: a current perspective.” Semin Oncol 30, no. 4 Suppl 13 (August 2003): 10–17. https://doi.org/10.1016/s0093-7754(03)00312-9.Full Text Link to Item
-
Dale, David C., Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman. “Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.” J Natl Compr Canc Netw 1, no. 3 (July 2003): 440–54. https://doi.org/10.6004/jnccn.2003.0038.Full Text Link to Item
-
Djulbegovic, Benjamin, Robert Coleman, Rolf Stahel, Debbie Singh, and Gary Lyman. “Evidence-based oncology in cancer treatment reviews.” Cancer Treat Rev 29, no. 1 (February 2003): 45–50. https://doi.org/10.1016/s0305-7372(02)00130-5.Full Text Link to Item
-
Haithcox, S., C. R. Ramnes, H. Lee, J. Lu, and G. H. Lyman. “The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: An observational study.” Bmc Nursing 2 (2003): 1–6. https://doi.org/10.1186/1472-6955-2-1.Full Text
-
Lyman, G. H. “Balancing the benefits and costs of colony-stimulating factors: A current perspective.” Seminars in Oncology 30, no. 4 SUPPL. 13 (2003): 10–17.
-
Clark, O. A. C., G. Lyman, A. A. Castro, L. G. O. Clark, and B. Djulbegovic. “Colony stimulating factors for chemotherapy induced febrile neutropenia.” Cochrane Database Syst Rev, no. 3 (2003): CD003039. https://doi.org/10.1002/14651858.CD003039.Full Text Link to Item
-
Lyman, Gary H., Nicole Kuderer, Olayemi Agboola, and Lodovico Balducci. “Evidence-based use of colony-stimulating factors in elderly cancer patients.” Cancer Control 10, no. 6 (2003): 487–99. https://doi.org/10.1177/107327480301000607.Full Text Link to Item
-
Adams, Jared R., Gary H. Lyman, Benjamin Djubegovic, Joe Feinglass, and Charles L. Bennett. “G-CSF as prophylaxis of febrile neutropenia in SCLC.” Expert Opin Pharmacother 3, no. 9 (September 2002): 1273–81. https://doi.org/10.1517/14656566.3.9.1273.Full Text Link to Item
-
Lyman, Gary H., Nicole M. Kuderer, and Lodovico Balducci. “Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients.” Curr Opin Hematol 9, no. 3 (May 2002): 207–14. https://doi.org/10.1097/00062752-200205000-00006.Full Text Link to Item
-
Lyman, Gary H., Nicole M. Kuderer, and Benjamin Djulbegovic. “Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.” Am J Med 112, no. 5 (April 1, 2002): 406–11. https://doi.org/10.1016/s0002-9343(02)01036-7.Full Text Link to Item
-
Ganguly, Rama, Gary Lyman, and Brandon Lenox. “Hepatitis B virus vaccine: cost effects and insurance coverage.” Am Clin Lab 21, no. 2 (March 2002): 44–46.Link to Item
-
Laufman, L., C. H. Spiridonidis, G. H. Lyman, N. M. Kuderer, and B. Djulbegovic. “Overlooking patient outcomes in a meta-analysis of trials of granulocyte colony-stimulating factor [1] (multiple letters).” American Journal of Medicine 113, no. 9 (2002): 766–68.
-
Lyman, Gary H., and Nicole M. Kuderer. “Filgrastim in patients with neutropenia: potential effects on quality of life.” Drugs 62 Suppl 1 (2002): 65–78. https://doi.org/10.2165/00003495-200262001-00005.Full Text Link to Item
-
Djulbegovic, B., J. R. Adams, G. H. Lyman, M. Lacevic, I. Hozo, M. Greenwich, and C. L. Bennett. “Evaluation and appraisal of randomized controlled trials in myeloma.” Ann Oncol 12, no. 11 (November 2001): 1611–17. https://doi.org/10.1023/a:1013181331874.Full Text Link to Item
-
Lyman, G. H. “Economic analysis of randomized, controlled trials.” Curr Oncol Rep 3, no. 5 (September 2001): 396–403. https://doi.org/10.1007/s11912-001-0025-4.Full Text Link to Item
-
Balch, C. M., S. J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, M. Urist, et al. “Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.” J Clin Oncol 19, no. 16 (August 15, 2001): 3622–34. https://doi.org/10.1200/JCO.2001.19.16.3622.Full Text Link to Item
-
Balducci, L., C. L. Hardy, and G. H. Lyman. “Hematopoietic growth factors in the older cancer patient.” Curr Opin Hematol 8, no. 3 (May 2001): 170–87. https://doi.org/10.1097/00062752-200105000-00008.Full Text Link to Item
-
Balducci, L., and G. H. Lyman. “Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.” J Clin Oncol 19, no. 5 (March 1, 2001): 1583–85. https://doi.org/10.1200/JCO.2001.19.5.1583.Full Text Link to Item
-
Bass, S. S., C. E. Cox, C. J. Salud, G. H. Lyman, C. McCann, E. Dupont, C. Berman, and D. S. Reintgen. “The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer.” J Am Coll Surg 192, no. 1 (January 2001): 9–16. https://doi.org/10.1016/s1072-7515(00)00771-7.Full Text Link to Item
-
Lyman, G. H., L. Balducci, and Y. Agboola. “Use of colony-stimulating factors in the elderly cancer patient.” Oncology Spectrums 2, no. 6 (2001): 414–21.
-
Lyman, G. H., and B. Djulbegovic. “Understanding economic analyses.” Evidence Based Oncology 2, no. 1 (2001): 2–5. https://doi.org/10.1054/ebon.2001.0095.Full Text
-
Djulbegovic, B., M. Lacevic, A. Cantor, K. K. Fields, C. L. Bennett, J. R. Adams, N. M. Kuderer, and G. H. Lyman. “The uncertainty principle and industry-sponsored research.” Lancet 356, no. 9230 (August 19, 2000): 635–38. https://doi.org/10.1016/S0140-6736(00)02605-2.Full Text Link to Item
-
Adams, V. R., and G. H. Lyman. “Interactive discussion on chemotherapy-related adverse events.” Pharmacotherapy 20, no. 7 Pt 2 (July 2000): 121S-125S. https://doi.org/10.1592/phco.20.10.121s.35231.Full Text Link to Item
-
Broeckel, J. A., P. B. Jacobsen, L. Balducci, J. Horton, and G. H. Lyman. “Quality of life after adjuvant chemotherapy for breast cancer.” Breast Cancer Res Treat 62, no. 2 (July 2000): 141–50. https://doi.org/10.1023/a:1006401914682.Full Text Link to Item
-
Lyman, G. H. “A predictive model for neutropenia associated with cancer chemotherapy.” Pharmacotherapy 20, no. 7 Pt 2 (July 2000): 104S-111S. https://doi.org/10.1592/phco.20.10.104s.35232.Full Text Link to Item
-
Stein, K. D., P. B. Jacobsen, D. M. Hann, H. Greenberg, and G. Lyman. “Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer.” J Pain Symptom Manage 19, no. 6 (June 2000): 436–45. https://doi.org/10.1016/s0885-3924(00)00142-1.Full Text Link to Item
-
Li, W., A. Stall, S. C. Shivers, J. Lin, F. Haddad, J. Messina, L. F. Glass, G. Lyman, and D. S. Reintgen. “Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma.” Ann Surg 231, no. 6 (June 2000): 795–803. https://doi.org/10.1097/00000658-200006000-00003.Full Text Link to Item
-
Djulbegovic, B., L. Morris, and G. H. Lyman. “Evidentiary challenges to evidence-based medicine.” J Eval Clin Pract 6, no. 2 (May 2000): 99–109. https://doi.org/10.1046/j.1365-2753.2000.00226.x.Full Text Link to Item
-
Extermann, M., L. Balducci, and G. H. Lyman. “What threshold for adjuvant therapy in older breast cancer patients?” J Clin Oncol 18, no. 8 (April 2000): 1709–17. https://doi.org/10.1200/JCO.2000.18.8.1709.Full Text Link to Item
-
Lyman, G. H. “A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.” Eur J Cancer 36 Suppl 1 (April 2000): S15–21. https://doi.org/10.1016/s0959-8049(99)00257-9.Full Text Link to Item
-
Pocock, S. J., R. A. Henderson, T. Clayton, G. H. Lyman, and D. A. Chamberlain. “Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina.” J Am Coll Cardiol 35, no. 4 (March 15, 2000): 907–14. https://doi.org/10.1016/s0735-1097(99)00637-3.Full Text Link to Item
-
Djulbegovic, B., I. Hozo, and G. H. Lyman. “Linking evidence-based medicine therapeutic summary measures to clinical decision analysis.” Medgenmed 2, no. 1 (January 13, 2000): E6.Link to Item
-
Djulbegovic, B., G. H. Lyman, and I. Hozo. “Talking about treatment.” Ann Intern Med 132, no. 1 (January 4, 2000): 94. https://doi.org/10.7326/0003-4819-132-1-200001040-00021.Full Text Link to Item
-
Cox, C. E., S. S. Bass, C. R. McCann, N. N. Ku, C. Berman, K. Durand, M. Bolano, et al. “Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer.” Annu Rev Med 51 (2000): 525–42. https://doi.org/10.1146/annurev.med.51.1.525.Full Text Link to Item
-
Halpern, S. D., J. H. T. Karlawish, R. Nuesch, T. Dieterle, B. Djulbegovic, C. L. Bennett, J. R. Adams, and G. H. Lyman. “Industry-sponsored research [5] (multiple letters).” Lancet 356, no. SUPPL. (2000): 2193–94. https://doi.org/10.1016/S0140-6736(05)72986-X.Full Text
-
Lyman, G. H. “A predictive model for neutropenia associated with cancer chemotherapy.” Pharmacotherapy 20, no. 7 II (2000): 104S-111S.
-
Saitz, R., K. M. Kessler, J. C. Peirce, B. P. Jain, B. Djulbegovic, G. H. Lyman, I. Hozo, and J. F. Steiner. “Talking about treatment [1] (multiple letters).” Annals of Internal Medicine 132, no. 1 (2000): 93–94.
-
Balducci, L., C. L. Hardy, and G. H. Lyman. “Hemopoietic reserve in the older cancer patient: clinical and economic considerations.” Cancer Control 7, no. 6 (2000): 539–47. https://doi.org/10.1177/107327480000700605.Full Text Link to Item
-
Djulbegovic, B., A. Cantor, G. H. Lyman, and J. C. Ruckdeschel. “Understanding treatment benefits and harms.” Evidence Based Oncology 1, no. 3 (2000): 66–68.
-
Jacobsen, P. B., D. M. Hann, L. M. Azzarello, J. Horton, L. Balducci, and G. H. Lyman. “Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates.” J Pain Symptom Manage 18, no. 4 (October 1999): 233–42. https://doi.org/10.1016/s0885-3924(99)00082-2.Full Text Link to Item
-
Bass, Siddharth S., Gary H. Lyman, Christa R. McCann, Ni Ni Ku, Claudia Berman, Kara Durand, Monica Bolano, et al. “Lymphatic Mapping and Sentinel Lymph Node Biopsy.” Breast J 5, no. 5 (September 1999): 288–95. https://doi.org/10.1046/j.1524-4741.1999.00001.x.Full Text Link to Item
-
Kamath, D., A. Brobeil, A. Stall, G. Lyman, C. W. Cruse, F. Glass, N. Fenske, J. Messina, C. Berman, and D. Reintgen. “Cutaneous lymphatic drainage in patients with grossly involved nodal basins.” Ann Surg Oncol 6, no. 4 (June 1999): 345–49. https://doi.org/10.1007/s10434-999-0345-4.Full Text Link to Item
-
Lyman, G. H., and L. Balducci. “Update of the economic analyses of the use of the colony-stimulating factors.” Curr Opin Hematol 6, no. 3 (May 1999): 145–51. https://doi.org/10.1097/00062752-199905000-00004.Full Text Link to Item
-
Schapira, D. V., C. Theodossiou, and G. H. Lyman. “The effects of NSAIDs on breast cancer prognostic factors.” Oncol Rep 6, no. 2 (1999): 433–35.Link to Item
-
Lyman, G. H., N. Kuderer, J. Greene, and L. Balducci. “The economics of febrile neutropenia: implications for the use of colony-stimulating factors.” Eur J Cancer 34, no. 12 (November 1998): 1857–64. https://doi.org/10.1016/s0959-8049(98)00222-6.Full Text Link to Item
-
Shivers, S. C., X. Wang, W. Li, E. Joseph, J. Messina, L. F. Glass, R. DeConti, et al. “Molecular staging of malignant melanoma: correlation with clinical outcome.” Jama 280, no. 16 (October 28, 1998): 1410–15. https://doi.org/10.1001/jama.280.16.1410.Full Text Link to Item
-
Joseph, E., M. Hyacinthe, G. H. Lyman, C. Busch, L. Demps, D. S. Reintgen, and C. E. Cox. “Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer.” Ann Surg Oncol 5, no. 6 (September 1998): 522–28. https://doi.org/10.1007/BF02303645.Full Text Link to Item
-
Lyman, G. H., N. M. Kuderer, and L. Balducci. “Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.” Curr Opin Oncol 10, no. 4 (July 1998): 291–96. https://doi.org/10.1097/00001622-199807000-00003.Full Text Link to Item
-
Lyman, G. H., N. M. Kuderer, and L. Balducci. “Cancer Care in the Elderly: Cost and Quality-of-Life Considerations.” Cancer Control 5, no. 4 (July 1998): 347–54. https://doi.org/10.1177/107327489800500408.Full Text Link to Item
-
Brobeil, A., C. Berman, C. W. Cruse, R. De Conti, A. Cantor, G. H. Lyman, E. Joseph, D. Rapaport, K. Wells, and D. S. Reintgen. “Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma.” Ann Surg Oncol 5, no. 4 (June 1998): 376–83. https://doi.org/10.1007/BF02303503.Full Text Link to Item
-
Broeckel, J. A., P. B. Jacobsen, J. Horton, L. Balducci, and G. H. Lyman. “Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.” J Clin Oncol 16, no. 5 (May 1998): 1689–96. https://doi.org/10.1200/JCO.1998.16.5.1689.Full Text Link to Item
-
Cox, C. E., S. Pendas, J. M. Cox, E. Joseph, A. R. Shons, T. Yeatman, N. N. Ku, et al. “Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.” Ann Surg 227, no. 5 (May 1998): 645–51. https://doi.org/10.1097/00000658-199805000-00005.Full Text Link to Item
-
Hann, D. M., P. B. Jacobsen, L. M. Azzarello, S. C. Martin, S. L. Curran, K. K. Fields, H. Greenberg, and G. Lyman. “Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.” Qual Life Res 7, no. 4 (May 1998): 301–10. https://doi.org/10.1023/a:1024929829627.Full Text Link to Item
-
Extermann, M., J. Overcash, G. H. Lyman, J. Parr, and L. Balducci. “Comorbidity and functional status are independent in older cancer patients.” J Clin Oncol 16, no. 4 (April 1998): 1582–87. https://doi.org/10.1200/JCO.1998.16.4.1582.Full Text Link to Item
-
Altman, D. G., and G. H. Lyman. “Methodological challenges in the evaluation of prognostic factors in breast cancer.” Breast Cancer Res Treat 52, no. 1–3 (1998): 289–303. https://doi.org/10.1023/a:1006193704132.Full Text Link to Item
-
Benson, K., S. J. Agosti, G. H. Lyman, J. M. Pow-Sang, H. I. Saba, and L. Balducci. “Estimated blood loss in group O as compared to non-group O radical prostatectomy patients.” Hematology 3, no. 3 (1998): 257–61.
-
Cox, C. E., M. Hyacinthe, R. J. Gonzalez, G. Lyman, D. Reintgen, N. N. Ku, M. S. Miller, H. Greenberg, and S. V. Nicosia. “Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: clinical outcome.” Ann Surg Oncol 4, no. 8 (December 1997): 644–49. https://doi.org/10.1007/BF02303749.Full Text Link to Item
-
Lyman, G. H., and N. M. Kuderer. “Basic population and cancer genetics and their use in the assessment of cancer risk.” Eur J Cancer 33, no. 13 (November 1997): 2160–66. https://doi.org/10.1016/s0959-8049(97)00307-9.Full Text Link to Item
-
Lyman, G. H., and N. M. Kuderer. “A Primer for Evaluating Clinical Trials.” Cancer Control 4, no. 5 (October 1997): 413–18. https://doi.org/10.1177/107327489700400504.Full Text Link to Item
-
Wells, K. E., D. P. Rapaport, C. W. Cruse, W. Payne, J. Albertini, C. Berman, G. H. Lyman, and D. S. Reintgen. “Sentinel lymph node biopsy in melanoma of the head and neck.” Plast Reconstr Surg 100, no. 3 (September 1997): 591–94. https://doi.org/10.1097/00006534-199709000-00006.Full Text Link to Item
-
Lyman, G. H., N. M. Kuderer, S. L. Lyman, M. Debus, S. Minton, L. Balducci, J. Horton, D. Reintgen, and C. Cox. “Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival.” Cancer Control 4, no. 4 (July 1997): 335–41. https://doi.org/10.1177/107327489700400405.Full Text Link to Item
-
Kumar, N. B., K. Allen, A. Cantor, C. E. Cox, H. Greenberg, S. Shah, and G. H. Lyman. “Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?” Breast Cancer Res Treat 44, no. 2 (June 1997): 135–43. https://doi.org/10.1023/a:1005721720840.Full Text Link to Item
-
Reintgen, D., E. Joseph, G. H. Lyman, T. Yeatman, L. Balducci, N. N. Ku, C. Berman, et al. “The Role of Selective Lymphadenectomy in Breast Cancer.” Cancer Control 4, no. 3 (May 1997): 211–19. https://doi.org/10.1177/107327489700400302.Full Text Link to Item
-
Reintgen, D., J. Albertini, G. Milliotes, J. Marshburn, C. W. Cruse, D. Rapaport, C. Berman, et al. “Investment in new technology research can save future health care dollars.” J Fla Med Assoc 84, no. 3 (March 1997): 175–81.Link to Item
-
Balducci, L., and G. H. Lyman. “Cancer in the elderly. Epidemiologic and clinical implications.” Clin Geriatr Med 13, no. 1 (February 1997): 1–14.Link to Item
-
Lyman, G. H., N. M. Kuderer, S. L. Lyman, C. E. Cox, D. Reintgen, and P. Baekey. “Importance of race on breast cancer survival.” Ann Surg Oncol 4, no. 1 (January 1997): 80–87. https://doi.org/10.1007/BF02316814.Full Text Link to Item
-
Yeatman, T. J., G. H. Lyman, S. K. Smith, D. S. Reintgen, A. B. Cantor, and C. E. Cox. “Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment.” Ann Surg Oncol 4, no. 3 (1997): 198–202. https://doi.org/10.1007/BF02306610.Full Text Link to Item
-
Albertini, J. J., G. H. Lyman, C. Cox, T. Yeatman, L. Balducci, N. Ku, S. Shivers, et al. “Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.” Jama 276, no. 22 (December 11, 1996): 1818–22.Link to Item
-
Miliotes, G., G. H. Lyman, C. W. Cruse, C. Puleo, P. A. Albertini, D. Rapaport, F. Glass, et al. “Evaluation of new putative tumor markers for melanoma.” Ann Surg Oncol 3, no. 6 (November 1996): 558–63. https://doi.org/10.1007/BF02306089.Full Text Link to Item
-
Webster, J., and G. H. Lyman. “Use of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.” Cancer Control 3, no. 6 (November 1996): 519–23.Link to Item
-
Lyman, G. H., S. Lyman, L. Balducci, N. Kuderer, D. Reintgen, C. Cox, P. Baekey, H. Greenberg, and J. Horton. “Age and the Risk of Breast Cancer Recurrence.” Cancer Control 3, no. 5 (October 1996): 421–27.Link to Item
-
Albertini, J. J., C. W. Cruse, D. Rapaport, K. Wells, M. Ross, R. DeConti, C. G. Berman, et al. “Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma.” Ann Surg 223, no. 2 (February 1996): 217–24. https://doi.org/10.1097/00000658-199602000-00016.Full Text Link to Item
-
Balducci, L., G. H. Lyman, and P. J. Fabri. “Management of cancer in the aged.” Compr Ther 22, no. 2 (February 1996): 88–93.Link to Item
-
Benson, K., L. Balducci, K. M. Milo, L. Heckel, and G. H. Lyman. “Patients' attitudes regarding out-of-hospital blood transfusion.” Transfusion 36, no. 2 (February 1996): 140–43. https://doi.org/10.1046/j.1537-2995.1996.36296181926.x.Full Text Link to Item
-
Extermann, M., L. Balducci, and G. H. Lyman. “Optimal duration of adjuvant tamoxifen treatment in elderly breast cancer patients: Influence of age, comorbidities, and various effectiveness hypotheses on life-expectancy and cost.” Breast Disease 9, no. 6 (1996): 327–39.
-
Miliotes, G., J. Albertini, C. Berman, R. Heller, J. Messina, F. Glass, W. Cruse, et al. “The tumor biology of melanoma nodal metastases.” Am Surg 62, no. 1 (January 1996): 81–88.Link to Item
-
Lyman, G. H., and L. Balducci. “A cost analysis of hematopoietic colony-stimulating factors.” Oncology (Williston Park) 9, no. 11 Suppl (November 1995): 85–91.Link to Item
-
Werner, M. H., S. Phuphanich, and G. H. Lyman. “The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly.” Cancer 76, no. 9 (November 1, 1995): 1634–42. https://doi.org/10.1002/1097-0142(19951101)76:9<1634::aid-cncr2820760921>3.0.co;2-0.Full Text Link to Item
-
Kumar, N. B., G. H. Lyman, K. Allen, C. E. Cox, and D. V. Schapira. “Timing of weight gain and breast cancer risk.” Cancer 76, no. 2 (July 15, 1995): 243–49. https://doi.org/10.1002/1097-0142(19950715)76:2<243::aid-cncr2820760214>3.0.co;2-r.Full Text Link to Item
-
Werner, M. H., S. Phuphanich, and G. H. Lyman. “Increasing Incidence of Primary Brain Tumors in the Elderly in Florida.” Cancer Control 2, no. 4 (July 1995): 309–14.Link to Item
-
Godellas, C. V., C. G. Berman, G. Lyman, C. W. Cruse, D. Rapaport, R. Heller, X. Wang, F. Glass, N. Fenske, and J. Messina. “The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases.” Am Surg 61, no. 2 (February 1995): 97–101.Link to Item
-
Berman, B. S., G. H. Lyman, O. F. Ballester, R. A. Sanderson, and A. S. D. Spiers. “Therapeutic use of granulocyte colony stimulating factor after induction chemotherapy in acute myelogenous leukemia: An analysis of clinical practice.” Hematology Reviews and Communications 9, no. 3 (1995): 213–21.
-
Lyman, G. H., and L. Balducci. “A cost analysis of hematopoietic colony-stimulating factors.” Oncology 9, no. 11 SUPPL. (1995): 85–91.
-
Reintgen, D., G. Lyman, T. Yeatman, and C. Cox. “Non-operative observation of mammographic abnormalities: Medical legal implications.” Breast Journal 1, no. 4 (1995): 262–67.
-
Reintgen, D., C. W. Cruse, K. Wells, C. Berman, N. Fenske, F. Glass, K. Schroer, R. Heller, M. Ross, and G. Lyman. “The orderly progression of melanoma nodal metastases.” Ann Surg 220, no. 6 (December 1994): 759–67. https://doi.org/10.1097/00000658-199412000-00009.Full Text Link to Item
-
Austin, P. F., C. W. Cruse, G. Lyman, K. Schroer, F. Glass, and D. S. Reintgen. “Age as a prognostic factor in the malignant melanoma population.” Ann Surg Oncol 1, no. 6 (November 1994): 487–94. https://doi.org/10.1007/BF02303614.Full Text Link to Item
-
Arango, H. A., C. S. Kalter, S. L. Decesare, J. V. Fiorica, G. H. Lyman, and W. N. Spellacy. “Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.” Obstet Gynecol 84, no. 4 Pt 2 (October 1994): 665–68.Link to Item
-
Lyman, G. H., and L. Balducci. “The effect of changing disease risk on clinical reasoning.” J Gen Intern Med 9, no. 9 (September 1994): 488–95. https://doi.org/10.1007/BF02599218.Full Text Link to Item
-
Schapira, D., P. Wolff, N. Kumar, J. Anderson, N. Aziz, G. Lyman, and M. Swanson. “The effect of weight-loss on estimated breast-cancer risk and sex-hormone levels.” Oncol Rep 1, no. 3 (May 1994): 613–17. https://doi.org/10.3892/or.1.3.613.Full Text Link to Item
-
Ballester, O. F., L. C. Moscinski, G. H. Lyman, J. V. Chaney, H. I. Saba, A. S. Spiers, and C. Klein. “High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma.” Blood 83, no. 7 (April 1, 1994): 1903–8.Link to Item
-
Arango, H. A., C. S. Kalter, S. L. Decasare, J. V. Fiorica, G. H. Lyman, and W. N. Spellacy. “Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.” Obstetrics and Gynecology 84, no. 4 II SUPPL. (1994): 665–68.
-
Crawford, J., H. Ozer, R. Stoller, D. Johnson, G. Lyman, I. Tabbara, M. Kris, et al. “Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.” Clinical Infectious Diseases 18 (January 1, 1994): S189–96. https://doi.org/10.1093/clinids/18.Supplement_2.S189.Full Text
-
Ward, T. T., R. G. Thomas, C. L. Fye, R. Arbeit, C. A. Coltman, W. Craig, B. W. Dana, S. M. Finegold, J. Lentino, and R. L. Penn. “Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study.” Clin Infect Dis 17, no. 3 (September 1993): 323–32. https://doi.org/10.1093/clinids/17.3.323.Full Text Link to Item
-
Balducci, L., K. Benson, G. H. Lyman, R. Sanderson, K. Fields, O. F. Ballester, and G. J. Elfenbein. “Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia.” Transfusion 33, no. 8 (August 1993): 665–70. https://doi.org/10.1046/j.1537-2995.1993.33893342749.x.Full Text Link to Item
-
Schapira, D. V., N. B. Kumar, and G. H. Lyman. “Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families.” Cancer 71, no. 9 (May 1, 1993): 2764–68. https://doi.org/10.1002/1097-0142(19930501)71:9<2764::aid-cncr2820710913>3.0.co;2-3.Full Text Link to Item
-
Lyman, G. H., C. G. Lyman, R. A. Sanderson, and L. Balducci. “Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.” J Natl Cancer Inst 85, no. 6 (March 17, 1993): 488–93. https://doi.org/10.1093/jnci/85.6.488.Full Text Link to Item
-
Reintgen, D., C. Cox, H. Greenberg, P. Baekey, S. Nicosia, C. Berman, R. Clark, and G. Lyman. “The medical legal implications of following mammographic breast masses.” Am Surg 59, no. 2 (February 1993): 99–105.Link to Item
-
Lyman, G. H., C. G. Lyman, R. A. Sanderson, and L. Balducci. “Response.” Journal of the National Cancer Institute 85, no. 15 (1993): 1252–53. https://doi.org/10.1093/jnci/85.15.1252.Full Text
-
Lyman, G. H., and L. Balducci. “Overestimation of test effects in clinical judgment.” J Cancer Educ 8, no. 4 (1993): 297–307. https://doi.org/10.1080/08858199309528246.Full Text Link to Item
-
Mayordomo, J. I., F. Rivera, M. T. Diaz-Puente, P. Lianes, H. Cortes-Funes, G. H. Lyman, C. G. Lyman, R. A. Sanderson, and L. Balducci. “Re: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy [4].” Journal of the National Cancer Institute 85, no. 15 (1993): 1251–53.
-
Reintgen, D., C. Berman, C. Cox, P. Baekey, S. Nicosia, H. Greenberg, C. Bush, G. H. Lyman, and R. A. Clark. “The anatomy of missed breast cancers.” Surg Oncol 2, no. 1 (1993): 65–75. https://doi.org/10.1016/0960-7404(93)90046-2.Full Text Link to Item
-
Stockwell, H. G., A. L. Goldman, G. H. Lyman, C. I. Noss, A. W. Armstrong, P. A. Pinkham, E. C. Candelora, and M. R. Brusa. “Environmental tobacco smoke and lung cancer risk in nonsmoking women.” J Natl Cancer Inst 84, no. 18 (September 16, 1992): 1417–22. https://doi.org/10.1093/jnci/84.18.1417.Full Text Link to Item
-
Lyman, G. H. “Risk factors for cancer.” Prim Care 19, no. 3 (September 1992): 465–79.Link to Item
-
Jacobs, C., G. Lyman, E. Velez-García, K. S. Sridhar, W. Knight, H. Hochster, L. T. Goodnough, J. E. Mortimer, L. H. Einhorn, and L. Schacter. “A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.” J Clin Oncol 10, no. 2 (February 1992): 257–63. https://doi.org/10.1200/JCO.1992.10.2.257.Full Text Link to Item
-
Fields, K. K., G. J. Elfenbein, R. A. Saleh, P. E. Zorsky, W. E. Janssen, J. B. Perkins, T. G. Saleh, et al. “Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: Focus on breast cancer and lymphoma.” Hematological Oncology 10, no. 1 (1992): 61–74.
-
Lyman, G. H., and A. S. Spiers. “Advances in current cancer treatment: an overview.” Hematol Oncol 10, no. 1 (1992): 3–6. https://doi.org/10.1002/hon.2900100103.Full Text Link to Item
-
Fiorica, J. V., W. S. Roberts, M. S. Hoffman, D. P. Barton, M. A. Finan, G. Lyman, and D. Cavanagh. “Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration.” Gynecol Oncol 43, no. 3 (December 1991): 265–69. https://doi.org/10.1016/0090-8258(91)90033-2.Full Text Link to Item
-
Balducci, L., D. V. Schapira, C. E. Cox, H. M. Greenberg, and G. H. Lyman. “Breast cancer of the older woman: an annotated review.” J Am Geriatr Soc 39, no. 11 (November 1991): 1113–23. https://doi.org/10.1111/j.1532-5415.1991.tb02879.x.Full Text Link to Item
-
Schapira, D. V., N. B. Kumar, G. H. Lyman, and W. F. Baile. “The effect of duration of intervention and locus of control on dietary change.” Am J Prev Med 7, no. 6 (November 1991): 341–47.Link to Item
-
Schapira, D. V., N. B. Kumar, G. H. Lyman, D. Cavanagh, W. S. Roberts, and J. LaPolla. “Upper-body fat distribution and endometrial cancer risk.” Jama 266, no. 13 (October 2, 1991): 1808–11.Link to Item
-
Crawford, J., H. Ozer, R. Stoller, D. Johnson, G. Lyman, I. Tabbara, M. Kris, J. Grous, V. Picozzi, and G. Rausch. “Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.” N Engl J Med 325, no. 3 (July 18, 1991): 164–70. https://doi.org/10.1056/NEJM199107183250305.Full Text Link to Item
-
Schapira, D. V., N. B. Kumar, and G. H. Lyman. “Estimate of breast cancer risk reduction with weight loss.” Cancer 67, no. 10 (May 15, 1991): 2622–25. https://doi.org/10.1002/1097-0142(19910515)67:10<2622::aid-cncr2820671037>3.0.co;2-j.Full Text Link to Item
-
Schapira, D. V., N. B. Kumar, and G. H. Lyman. “Obesity, body fat distribution, and sex hormones in breast cancer patients.” Cancer 67, no. 8 (April 15, 1991): 2215–18. https://doi.org/10.1002/1097-0142(19910415)67:8<2215::aid-cncr2820670836>3.0.co;2-q.Full Text Link to Item
-
Schapira, D. V., N. B. Kumar, G. H. Lyman, and C. E. Cox. “Obesity and body fat distribution and breast cancer prognosis.” Cancer 67, no. 2 (January 15, 1991): 523–28. https://doi.org/10.1002/1097-0142(19910115)67:2<523::aid-cncr2820670234>3.0.co;2-o.Full Text Link to Item
-
Johnson, D. H., J. C. Ruckdeschel, J. H. Keller, G. H. Lyman, G. J. Kallas, J. Macdonald, R. C. DeConti, et al. “A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.” Cancer 67, no. 1 SUPPL. (1991): 245–49.
-
Johnson, D. H., J. C. Ruckdeschel, J. H. Keller, G. H. Lyman, G. J. Kallas, J. Macdonald, R. C. DeConti, J. Lee, Q. S. Ringenberg, and W. P. Patterson. “A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer.” Cancer 67, no. 1 Suppl (January 1, 1991): 245–49. https://doi.org/10.1002/1097-0142(19910101)67:1+<245::aid-cncr2820671306>3.0.co;2-z.Full Text Link to Item
-
Schapira, D. V., N. B. Kumar, and G. H. Lyman. “Serum cholesterol reduction with tamoxifen.” Breast Cancer Res Treat 17, no. 1 (November 1990): 3–7. https://doi.org/10.1007/BF01812678.Full Text Link to Item
-
Rao, K. J., G. Lyman, K. Hamsbhushanam, J. P. Scott, and P. Jagadeeswaran. “Human factor IXLincoln Park: a molecular characterization.” Mol Cell Probes 4, no. 5 (October 1990): 335–40. https://doi.org/10.1016/0890-8508(90)90024-t.Full Text Link to Item
-
Hoffman, M., K. Molpus, W. S. Roberts, G. H. Lyman, and D. Cavanagh. “Tuboovarian abscess in postmenopausal women.” J Reprod Med 35, no. 5 (May 1990): 525–28.Link to Item
-
Morris, D. J., C. Muus, and G. H. Lyman. “Abdominal pain and a pelvic mass.” Hosp Pract (Off Ed) 25, no. 4A (April 30, 1990): 80–88.Link to Item
-
Schapira, D. V., N. B. Kumar, G. H. Lyman, and C. E. Cox. “Abdominal obesity and breast cancer risk.” Ann Intern Med 112, no. 3 (February 1, 1990): 182–86. https://doi.org/10.7326/0003-4819-112-3-182.Full Text Link to Item
-
Morris, D. J., C. Muus, and G. L. Lyman. “Abdominal pain and a pelvic mass.” Hospital Practice 25, no. 4 A (1990): 80+85-86+88.
-
Schapira, D. V., N. B. Kumar, G. H. Lyman, and S. C. McMillan. “The value of current nutrition information.” Prev Med 19, no. 1 (January 1990): 45–53. https://doi.org/10.1016/0091-7435(90)90006-6.Full Text Link to Item
-
Morris, D. J., G. H. Lyman, and C. Muus. “Extra-medullary relapse of acute myeloid leukemia at phlebotomy and bone marrow sites.” Hematology Reviews and Communications 4, no. 4 (1990): 229–35.
-
Jagadeeswaran, P., S. V. Reddy, K. J. Rao, K. Hamsabhushanam, and G. Lyman. “Cloning and characterization of the 5' end (exon 1) of the gene encoding human factor X.” Gene 84, no. 2 (December 14, 1989): 517–19. https://doi.org/10.1016/0378-1119(89)90529-5.Full Text Link to Item
-
Goldschmid, S., H. W. Boyce, J. I. Brown, P. G. Brady, H. J. Nord, and G. H. Lyman. “A new objective measurement of esophageal lumen patency.” Am J Gastroenterol 84, no. 10 (October 1989): 1255–58.Link to Item
-
Hoffman, M. S., W. S. Roberts, D. Cavanagh, H. Praphat, P. Solomon, and G. H. Lyman. “Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.” Gynecol Oncol 35, no. 1 (October 1989): 75–77. https://doi.org/10.1016/0090-8258(89)90016-4.Full Text Link to Item
-
Roberts, W. S., D. Cavanagh, V. C. Roberts, S. Hewitt, and G. H. Lyman. “Wound hematoma: prophylaxis with topical thrombin.” South Med J 82, no. 5 (May 1989): 607–9.Link to Item
-
Morris, D. J., G. H. Lyman, and C. Muus. “Impetiginous lesions in recurrent AML.” Hosp Pract (Off Ed) 24, no. 3A (March 30, 1989): 153–56.Link to Item
-
Wickstrom, E. L., T. A. Bacon, A. Gonzalez, G. H. Lyman, and E. Wickstrom. “Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells.” In Vitro Cell Dev Biol 25, no. 3 Pt 1 (March 1989): 297–302. https://doi.org/10.1007/BF02628470.Full Text Link to Item
-
Morris, D. J., G. H. Lyman, and C. Muus. “Impetiginous lesions in recurrent AML.” Hospital Practice 24, no. 3 A (1989): 153–56.
-
Wickstrom, E. L., A. B. Th, A. Gonzalez, G. H. Lyman, and E. Wickstrom. “Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells.” In Vitro Cellular and Developmental Biology Animal 25, no. 3 I (1989): 297–302.
-
Stockwell, H. G., G. H. Lyman, J. Waltz, and J. T. Peters. “Lung cancer in Florida. Risks associated with residence in the central Florida phosphate mining region.” Am J Epidemiol 128, no. 1 (July 1988): 78–84. https://doi.org/10.1093/oxfordjournals.aje.a114961.Full Text Link to Item
-
Weston, M. W., S. P. Glasser, D. J. Stoner, and G. H. Lyman. “Clinical assessment of beta blockade.” Clin Cardiol 11, no. 5 (May 1988): 311–16. https://doi.org/10.1002/clc.4960110508.Full Text Link to Item
-
Wickstrom, E. L., T. A. Bacon, A. Gonzalez, D. L. Freeman, G. H. Lyman, and E. Wickstrom. “Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.” Proc Natl Acad Sci U S A 85, no. 4 (February 1988): 1028–32. https://doi.org/10.1073/pnas.85.4.1028.Full Text Link to Item
-
Hoffman, M. S., W. S. Roberts, S. C. Bryson, J. J. Kavanagh, D. Cavanagh, and G. H. Lyman. “Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide.” Gynecol Oncol 29, no. 1 (January 1988): 32–36. https://doi.org/10.1016/0090-8258(88)90143-6.Full Text Link to Item
-
Clark, P. I., S. P. Glasser, G. H. Lyman, J. Krug-Fite, and A. Root. “Relation of results of exercise stress tests in young women to phases of the menstrual cycle.” Am J Cardiol 61, no. 1 (January 1, 1988): 197–99. https://doi.org/10.1016/0002-9149(88)91334-3.Full Text Link to Item
-
Stockwell, H. G., and G. H. Lyman. “Cigarette smoking and the risk of female reproductive cancer.” Am J Obstet Gynecol 157, no. 1 (July 1987): 35–40. https://doi.org/10.1016/s0002-9378(87)80341-1.Full Text Link to Item
-
Roberts, W. S., D. Cavanagh, S. C. Bryson, G. H. Lyman, and S. Hewitt. “Major morbidity after pelvic exenteration: a seven-year experience.” Obstet Gynecol 69, no. 4 (April 1987): 617–21.Link to Item
-
Lyman, G. H., W. R. Vogler, and M. Raney. “Continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial.” Cancer Treat Rep 71, no. 3 (March 1987): 309–10.Link to Item
-
Yangco, B. G., C. De Lerma, G. H. Lyman, and D. L. Price. “Clinical study evaluating efficacy of praziquantel in clonorchiasis.” Antimicrob Agents Chemother 31, no. 2 (February 1987): 135–38. https://doi.org/10.1128/AAC.31.2.135.Full Text Link to Item
-
Endicott, J. N., R. Jensen, and G. Lyman. “Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the head and neck contracts program.” Cancer 60, no. 3 (1987): 301–11. https://doi.org/10.1002/1097-0142(19870801)60:3<301::AID-CNCR2820600306>3.0.CO;2-V.Full Text
-
Lyman, G. H., and C. G. Lyman. “Leukemia and groundwater contamination.” Jama 256, no. 19 (November 21, 1986): 2676–77.Link to Item
-
Cintron, G., R. Medina, A. A. Reyes, and G. Lyman. “Cardiovascular effects and safety of dental anesthesia and dental interventions in patients with recent uncomplicated myocardial infarction.” Arch Intern Med 146, no. 11 (November 1986): 2203–4.Link to Item
-
Roberts, W. S., S. C. Bryson, D. Cavanagh, V. C. Roberts, and G. H. Lyman. “Peritoneal cytology and invasive carcinoma of the cervix.” Gynecol Oncol 24, no. 3 (July 1986): 331–36. https://doi.org/10.1016/0090-8258(86)90310-0.Full Text Link to Item
-
Schocken, D. D., B. E. Robinson, J. Krug-Fite, G. H. Lyman, and P. P. Barry. “Digitalis use in a retirement community.” J Am Geriatr Soc 34, no. 7 (July 1986): 504–6. https://doi.org/10.1111/j.1532-5415.1986.tb04241.x.Full Text Link to Item
-
Limberg, M. B., C. E. Margo, and G. H. Lyman. “Eosinophils in corneas removed by penetrating keratoplasty.” Br J Ophthalmol 70, no. 5 (May 1986): 343–46. https://doi.org/10.1136/bjo.70.5.343.Full Text Link to Item
-
Dinwoodie, W. R., A. A. Bartolucci, G. H. Lyman, E. Velez-Garcia, O. J. Martelo, and P. R. Sarma. “Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial.” Cancer Treat Rep 70, no. 2 (February 1986): 267–70.Link to Item
-
Stockwell, H. G., and G. H. Lyman. “Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck.” Head Neck Surg 9, no. 2 (1986): 104–10. https://doi.org/10.1002/hed.2890090206.Full Text Link to Item
-
Lyman, G. H., C. G. Lyman, and W. Johnson. “Association of leukemia with radium groundwater contamination.” Jama 254, no. 5 (August 2, 1985): 621–26.Link to Item
-
Marsden, D. E., D. Cavanagh, B. J. Wisniewski, W. S. Roberts, and G. H. Lyman. “Factors affecting the incidence of infectious morbidity after radical hysterectomy.” Am J Obstet Gynecol 152, no. 7 Pt 1 (August 1, 1985): 817–21. https://doi.org/10.1016/s0002-9378(85)80069-7.Full Text Link to Item
-
Lyman, G. H., C. G. Lyman, and W. Johnson. “Leukemia associated with radium groundwater contamination.” Proceedings of the American Association for Cancer Research VOL. 26 (1985): No.813.
-
Marsden, D. E., D. Cavanagh, B. J. Wisniewski, W. S. Roberts, and G. H. Lyman. “Factors affecting the incidence of infectious morbidity after radical hysterectomy.” American Journal of Obstetrics and Gynecology 152, no. 7 I (1985): 817–21.
-
Lyman, G. H., C. C. Williams, W. R. Dinwoodie, and D. D. Schocken. “Sudden death in cancer patients receiving lithium.” J Clin Oncol 2, no. 11 (November 1984): 1270–76. https://doi.org/10.1200/JCO.1984.2.11.1270.Full Text Link to Item
-
Cassileth, P. A., G. H. Lyman, J. M. Bennett, J. H. Glick, and M. M. Oken. “High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.” Am J Clin Oncol 7, no. 4 (August 1984): 361–63. https://doi.org/10.1097/00000421-198408000-00013.Full Text Link to Item
-
Lyman, G. H. “Medical and public health consequences of nuclear war on the State of Florida.” J Fla Med Assoc 69, no. 12 (December 1982): 997–1001.Link to Item
-
Lyman, G. H., C. C. Williams, D. Preston, A. Goldman, W. R. Dinwoodie, H. Saba, R. Hartmann, R. Jensen, and L. Shukovsky. “Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy.” Am J Med 70, no. 6 (June 1981): 1222–29. https://doi.org/10.1016/0002-9343(81)90831-7.Full Text Link to Item
-
Breen, J. F., S. Maglio, H. I. Saba, and G. H. Lyman. “Prophylactic antibiotics in hospitalized granulocytopenic patients.” Clinical Research 29, no. 5 (1981): 835A.
-
Dinwoodie, W. R., G. H. Lyman, C. C. Williams, and A. Richman. “Intensive combination chemotherapy and radiotherapy for small cell bronchogenic carcinoma (SCBC).” Proceedings of the American Association for Cancer Research Vol. 22 (1981): C–675.
-
Lyman, G. H., C. C. Williams, W. R. Dinwoodie, and D. Johnson. “Early death in patients with electrocardiographic (EKG) abnormalities receiving lithium carbonate (LC).” Proceedings of the American Association for Cancer Research Vol. 22 (1981): C–358.
-
Lyman, G. H., and C. C. Williams. “Serum lithium level and the attenuation of chemotherapy myelosuppression.” Proceedings of the American Association for Cancer Research Vol. 22 (1981): 702-.
-
Williams, C. C., and G. H. Lyman. “Cis-diamminedichloroplatinum (CDDP) and bleomycin (B) in advanced squamous cell carcinoma of the head and neck (SCCHN).” Proceedings of the American Association for Cancer Research Vol. 22 (1981): C–782.
-
Lyman, G. H. “Adjunctive agents in systemic chemotherapy.” Compr Ther 6, no. 10 (October 1980): 16–25.Link to Item
-
Lyman, G. H., C. C. Williams, and D. Preston. “The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy.” N Engl J Med 302, no. 5 (January 31, 1980): 257–60. https://doi.org/10.1056/NEJM198001313020503.Full Text Link to Item
-
Lyman, G. H., C. C. Williams, W. R. Dinwoodie, and D. Preston. “The effect of lithium carbonate administration in patients with advanced small cell bronchogenic carcinoma receiving combination chemotherapy and radiotherapy.” Adv Exp Med Biol 127 (1980): 207–29. https://doi.org/10.1007/978-1-4757-0259-0_16.Full Text Link to Item
-
Lyman, G. H., S. Armistead, and C. C. Williams. “Bleomycin and prolonged infusion cis-diamminedichloroplatinum (CDDP) in advanced squamous cell carcinoma of the head and neck (SCCHN).” Clinical Research 27, no. 5 (1979): 759A.
-
Lyman, G. H., and M. J. Gilio. “Ultrastructural alterations associated with dimethylsulfoxide (DMSO) induced Friend erythroleukemia cell (FLC) differentiation in vitro: Cell surface analysis.” Proceedings of the American Association for Cancer Research Vol. 20 (1979): No.1174.
-
Williams, C. C., G. H. Lyman, and W. R. Dinwoodie. “Treatment results and toxicity of lithium carbonate (L) in the combined modality management of small cell lung cancer.” Proceedings of the American Association for Cancer Research Vol. 20 (1979): No.C-572.
-
Lyman, G. H., R. C. Hartmann, H. I. Saba, D. Preston, L. Shukovsky, R. Jensen, and M. Knight. “Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma.” South Med J 71, no. 5 (May 1978): 519–29. https://doi.org/10.1097/00007611-197805000-00013.Full Text Link to Item
-
Lyman, G. H., R. E. Bettigole, E. Robson, J. L. Ambrus, and H. Urban. “Fibrinogen kinetics in patients with neoplastic disease.” Cancer 41, no. 3 (March 1978): 1113–22. https://doi.org/10.1002/1097-0142(197803)41:3<1113::aid-cncr2820410346>3.0.co;2-d.Full Text Link to Item
-
Lyman, G. H., R. C. Hartmann, and H. I. Saba. “Combination chemotherapy and radiation therapy of oat cell bronchogenic carcinoma.” Clinical Research 26, no. 1 (1978): 36A.
-
Lyman, G. H., and H. D. Preisler. “Carcinoma of unknown primary: natural history and response to therapy.” J Med 9, no. 6 (1978): 445–59.Link to Item
-
Lyman, G. H., and P. Garms. “Effect of divalent cations and combinations of cryoprotective agents (C) on the cryopreservation of human erythrocytes (E).” Clinical Research 26, no. 6 (1978): 765A.
-
Preisler, H. D., and G. H. Lyman. “Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy.” Am J Hematol 3 (1977): 209–18. https://doi.org/10.1002/ajh.2830030301.Full Text Link to Item
-
Lyman, G. H., D. Papahadjopoulos, and H. D. Preisler. “Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of Friend leukemic cell differentiation.” Biochim Biophys Acta 448, no. 3 (October 19, 1976): 460–73. https://doi.org/10.1016/0005-2736(76)90300-x.Full Text Link to Item
-
Lyman, G. H., H. D. Preisler, and D. Papahadjopoulos. “Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation.” Nature 262, no. 5567 (July 29, 1976): 361–63. https://doi.org/10.1038/262360a0.Full Text Link to Item
-
Preisler, H. D., S. Bjornsson, M. Mori, and G. H. Lyman. “Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration.” Br J Cancer 33, no. 6 (June 1976): 634–45. https://doi.org/10.1038/bjc.1976.101.Full Text Link to Item
-
Lyman, G. H., H. D. Preisler, and D. Papahadjopoulos. “Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation.” Nature 262, no. 5567 (1976): 360–63.
-
Preisler, H. D., and G. Lyman. “Differentiation of erythroleukemia cells in vitro: properties of chemical inducers.” Cell Differ 4, no. 3 (June 1975): 179–85. https://doi.org/10.1016/0045-6039(75)90039-1.Full Text Link to Item
-
-
Conference Papers
-
De Rosa, N., G. H. Lyman, D. Silbermins, M. E. Valsecchi, S. Wong, S. K. Pruitt, and W. T. Lee. “Systematic review of 99mTc human serum albumin and 99mTc sulfur colloid studies of sentinel lymph node biopsy of cutaneous melanoma of the head and neck.” In Laryngoscope, Vol. 121, 2011. https://doi.org/10.1002/lary.21983.Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.